Stockwinners Market Radar for December 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:02 EST Seacoast Banking board renews share repurchase program - Seacoast Banking Corporation of Florida announced that its Board of Directors has renewed the company's share repurchase program. Under the repurchase program, which will expire on December 31, 2023, the company may repurchase, from time to time, up to $100M of its shares of common stock, representing approximately 4% of the company's outstanding common stock. The repurchase program permits shares to be repurchased in the open market, by block purchase, in privately negotiated transactions, in one or more transactions from time to time, or pursuant to any trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Exchange Act and other applicable legal and regulatory requirements.

18:37 EST Bionomics names Spyridon Papapetropoulos president, CEO - Bionomics announced that it has appointed Spyridon "Spyros" Papapetropoulos, M.D. as President and Chief Executive Officer, effective 5 January 2023. Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and will resume the role of Non-Executive Chairman of the Board of Directors effective 1 January 2023. Dr. De Souza commented "Bionomics is at a key inflection point in its development and potential transition from an early-stage development organization to a later stage clinical development and commercial organization as we await the data from our two ongoing Phase 2 clinical trials of BNC210 for the acute treatment of social anxiety disorder and chronic treatment of post-traumatic stress disorder by year end 2022 and mid-2023, respectively. Having led the Company turn around over the past three years, I am delighted to hand over the reins to Spyros to leverage his extensive experience in leading R&D and commercial organizations in both the private and public sector and small biotech and large pharmaceutical companies to continue to progress the pipeline and in doing so, build value for patients and shareholders. I will continue to be closely involved with Bionomics in my oversight role as Non-Executive Chairman of the Board."

18:30 EST Astellas Pharma says zolbetuximab met primary endpoint in Phase 3 GLOW trial - Astellas Pharma announced positive topline results from the Phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class Claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The GLOW study met its primary endpoint showing statistical significance in progression-free survival (PFS) for patients treated with zolbetuximab plus CAPOX compared to placebo plus CAPOX. In addition, the study met a key secondary endpoint, overall survival (OS), showing statistical significance for patients treated with zolbetuximab plus CAPOX compared to placebo plus CAPOX. The most frequent treatment-emergent adverse events (TEAEs) were nausea and vomiting. Detailed results will be presented at a future scientific congress and submitted for publication.

17:48 EST Adobe says regulatory process for Figma acquisition is proceeding as expected - Says currently in DOJ's second request process for the acquisition. Says getting a lot of great feedback from customers on Figma. Says experienced strong customer purchasing during peak holiday weeks. Says drove strong EPS performance in the quarter. Says GAAP tax rate came in lower than expected. Says innovation has come through close relationship with customers. Says saw great strength across all creative segments. Says focused a lot on new campaigns to attract audiences for creative. Comments taken from Q4 earnings conference call.

17:28 EST Four Corners Property Trust announces disposition of Red Lobster property - Four Corners Property Trust announced the disposition of a Red Lobster property for $4.9M. The property is located in Ohio and is corporate-operated under a triple net lease. The transaction was priced at cap rate in range with previous FCPT dispositions. The company plans to repurpose the proceeds into new investment opportunities consistent with FCPT thresholds. FCPT anticipates redeploying the proceeds from this transaction through an Internal Revenue Code Section 1031 like-kind exchange. As a result, net cash proceeds from the sale will be held in an escrow account until one or more properties are purchased through the 1031-Exchange. However, there can be no assurance that an acquisition of a new property or properties will occur. If the company fails to identify one or more like-kind replacement properties of comparable value within 45 days of the date of sale and/or fails to acquire such property or properties within 180 days of the date of sale, the company will be required to pay a tax at the highest corporate income tax rate on any gain recognized on the sale of this property.

17:22 EST Oshkosh awarded $543.48M Army contract modification - Oshkosh was awarded a $543.48M modification to a contract to exercise available options to support the fielding of the Joint Light Tactical Vehicle Family of Vehicles. Work will be performed in Oshkosh, Wisconsin, with an estimated completion date of July 31, 2024. U.S. Army Contracting Command is the contracting activity.

17:19 EST Ocugen's OCU400 granted Orphan Drug designations for two diseases - Ocugen's OCU400 - human nuclear hormone receptor subfamily 2 group E member 3 - has been granted orphan drug designations by the FDA for the treatment of retinitis pigmentosa and Leber congenital amaurosis. Currently, RP is associated with mutations in more than 100 genes, affecting approximately 110,000 people in the U.S. LCA is associated with mutations in more than 25 genes, affecting approximately 10,000 people in the U.S. There are currently no treatment options available for patients living with RP and LCA, and OCU400 has the potential to treat both with a single product.

17:11 EST American Electric falls after FERC denies sale of Kentucky Transmission - The Federal Energy Regulatory Commission posted on order its website with "denies, without prejudice, authorization, pursuant to section 203 of the Federal Power Act, for a proposed transaction where Liberty Utilities Co. seeks to acquire all issued and outstanding common shares of AEP Kentucky Transmission Company, Inc. and Kentucky Power Company." Shares of American Electric Power (AEP) closed down 3% to $95.57 following the post. Reference Link

17:05 EST Camber Energy approves 1-for-50 reverse stock split - Camber Energy approved a 1-for-50 reverse stock split of the company's issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the company's authorized shares of common stock such that, following the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 1,000,000,000 to 20,000,000. The reverse stock split is anticipated to be effective as of the open of the market on December 30. The number of outstanding common shares will be reduced from approximately 814.4 million shares to approximately 16.3 million shares. Any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis. The Board of Directors approved the Reverse Stock Split solely to enable the company to expeditiously meet the low price per share selling price requirements of the NYSE American and to reduce the risk of the company being automatically delisted from the NYSE American. The company anticipates that the effective time of the Reverse Stock Split will be before market open on December 30, with the common stock trading on a post-split basis under the company's existing trading symbol, "CEI," at the market open on December 30, 2022 with a new CUSIP number, 13200M 607. The Reverse Stock Split will bring the company into compliance with the listing requirements of the NYSE American.

16:56 EST Apple TV+ announces new 'Mythic Quest' spinoff series 'Mere Mortals' - Apple TV+ announced that its comedy series "Mythic Quest" will expand its universe of beloved characters with "Mere Mortals," a new eight-episode extension series from Ashly Burch, John Howell Harris and Katie McElhenney, with Megan Ganz, Rob McElhenney, David Hornsby and Charlie Day serving as executive producers. "Mere Mortals" will explore the lives of employees, players and fans who are impacted by the game. The new extension series takes a page out of the acclaimed departure episodes of "Mythic Quest," including the upcoming episode "Sarian," set to make its global debut on Apple TV+ this Friday; last year's "Everlight," the special episode that earned a Primetime Emmy Award nomination for Outstanding Narrator for Anthony Hopkins; season one's "A Dark Quiet Death"; "Backstory!" from "Mythic Quest" season two; and, the widely celebrated standalone episode, "Mythic Quest: Quarantine."

16:43 EST Pediatrix Medical names James Swift, M.D as CEO, succeeding Mark Ordan - Pediatrix Medical announced that the company's board of directors has appointed James Swift, M.D., as CEO, to succeed Mark Ordan, who has been named executive chair of the company's board of directors and has served as CEO since July 2020. Guy Sansone, who previously served as chair of the company's board of directors since July 2020, has been named lead independent director. Each of these transitions will go into effect at the end of the year. Dr. Swift joined the company in 2009 through the acquisition of a multi-state pediatric specialty practice, Children's HealthCare Network, which he founded in 1996 and where he served as CEO.

16:33 EST Lanvin Group debuts on NYSE under "LANV" ticker - Lanvin Group (LANV) and Primavera Capital Acquisition (PV) completed their business combination and the listing of the shares and warrants of Lanvin Group under the new ticker symbols "LANV" and "LANVW." The proceeds of the transaction will be used to accelerate the organic growth of the Group's brand portfolio and to fund strategic acquisitions that enrich its luxury fashion portfolio. The transaction received support from a roster of investors ahead of the listing, including an aggregate $193M of fully committed PIPE subscription and forward purchase from Fosun International, ITOCHU, Stella International, Baozun Hong Kong Investment, Golden A&A, Handsome and Aspex Master Fund. Fosun Fashion (Cayman) also upsized its PIPE subscription investment from $38M to approximately $133M, including the conversion of approximately $95M in existing shareholder loans and accrued interest into equity. In addition, Meritz Securities made a $50M equity investment in the Group in a private placement. In the first six months of 2022, the Group recorded revenue of EUR202M, representing growth of 73%, compared to the same period in 2021.

16:32 EST Hudson Acquisition I receives noncompliance notification from Nasdaq - Hudson Acquisition I announced that on December 9, the company received a notice from the Nasdaq indicating that as a result of the delinquency in the timely filing of the company's quarterly report on Form 10-Q for the period ended September 30, the company is out of compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. As a result of the delinquency, the company must submit its original plan to regain compliance with the Listing Rule within sixty calendar days from the Notice, and if Nasdaq accepts the plan, Nasdaq may grant an extension of one hundred eighty calendar days from the 10-Q due date, or until May 29, 2023, to regain compliance. The current notice will have no immediate effect on the listing or trading of the company's common stock on the Nasdaq. While the company can provide no assurances as to timing, the company's management is working diligently to complete the Form 10-Q and plans to file the Form 10-Q as soon as practicably possible to regain compliance with the Listing Rule.

16:27 EST Vimeo reports November revenue down 1% - Reports November subscribers down 4%. Reports November average revenue per user up 2%.

16:26 EST LPL Financial reports monthly activity for November - LPL Financial released its monthly activity report for November. Total advisory and brokerage assets at the end of November were $1.14T, an increase of $49.3B, or 4.5%, compared to the end of October 2022. Total net new assets for November were $5.6B, translating to a 6.2% annualized growth rate. This included $0.2B of brokerage assets from People's United that onboarded in November. Total net new advisory assets were $3.6B, translating to a 7.6% annualized growth rate. Total client cash balances at the end of November were $62.5B, a decrease of $2.7B compared to the end of October 2022. Net buying in November was $9.4B.

16:22 EST Imperial Petroleum receives noncompliance notification from Nasdaq - Imperial Petroleum announced that the company received formal notification from the Listing Qualification Department of the Nasdaq notifying the company that it has been granted an additional 180-day compliance period, or until June 12, 2023, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550.

16:20 EST Manchester United, TeamViewer reach agreement on future partnership - Manchester United (MANU) and TeamViewer (TMVWY) have reached a mutually-beneficial agreement under which Manchester United shall have the option to buy back the rights to the club's shirt front sponsorship. Having agreed its partnership with TeamViewer at the height of the Covid-19 pandemic, Manchester United will be taking the opportunity to commence a focused sales process for a new shirt front partner in a normalised market.

16:19 EST Quanex says would be premature to give guidance at this time - The company said, "Our long-term view continues to be optimistic as the underlying fundamentals for the residential housing market remain positive. However, like last year, based on current macro indicators and recent conversations with our customers, we are taking a measured approach to 2023 guidance. As such, we believe it would be premature to give guidance at this time. We intend to re-visit guidance when we report earnings for the first quarter."

16:18 EST D.R. Horton acquires homebuilding operations of Riggins Custom Homes - D.R. Horton announced the acquisition of Riggins Custom Homes, one of the largest builders in Northwest Arkansas. The homebuilding assets of Riggins Custom Homes and related entities acquired include approximately 3,000 lots, 170 homes in inventory and 173 homes in sales order backlog. For the trailing twelve months ended November 30, 2022, Riggins closed 153 homes with an average home size of approximately 1,925 square feet and an average sales price of $313,600. D.R. Horton expects to pay approximately $107 million in cash for the purchase, and the Company plans to combine the Riggins operations with the current D.R. Horton platform in Northwest Arkansas. Donald R. Horton, Chairman of the Board, said, "We are excited for the Riggins team to join the D.R. Horton family. Their quality building operations and local market expertise make Riggins an excellent extension as we grow our local start-up market position in Northwest Arkansas."

16:17 EST Synovus names Kevin Blair chairman of the board - Synovus Financial announced the appointment of President and Chief Executive Officer Kevin Blair to chairman of the board, effective Jan. 1, 2023. Blair succeeds Kessel D. Stelling, who is retiring as chairman on Dec. 31, 2022, and will continue in an advisory role with the company until Jan. 1, 2025, as previously announced. Blair has served as president and CEO of Synovus since April 2021. He joined Synovus in 2016 as executive vice president and chief financial officer. Blair was appointed senior executive vice president, chief operating officer in 2018.

16:16 EST Hersha Hospitality announces 50c per share special dividend - Hersha Hospitality announced its board of trustees has approved a special dividend of 50c per common share and per limited partnership unit for the year ending December 31. In addition to this special dividend, the board also approved a cash dividend of 5c per common share and per limited partnership unit for the fourth quarter ending December 31. These common share dividends and limited partnership unit distributions are both payable on January 18, 2023, to holders of record as of December 30.

16:15 EST Nurix Therapeutics receives FDA clearance for NX-5948 IND application - Nurix Therapeutics announced that it has received clearance from the FDA for the company's investigational new drug, or IND, application to expand the ongoing Phase 1 clinical program for NX-5948 into sites in the United States.

16:11 EST Enservco receives noncompliance notice from NYSE - Enservco announced it has received a notice of noncompliance from NYSE Regulation because the company's stockholders' equity of approximately $5.2M for the second quarter ended June 30, was below the required minimum level of $6M. This NYSE notice has no immediate effect on the listing or trading of the company's common stock. On or before January 9, 2023, Enservco is required to submit a plan to cure the deficiency and regain compliance with continued listing standards. If the NYSE accepts such plan, Enservco will have 18 months - or until June 9, 2024 - to regain compliance.

16:10 EST Zai Lab presents new interim OS data from NORA study - Zai Lab presented new interim overall survival, or OS, data in Chinese patients with platinum-sensitive recurrent ovarian cancer, or PSROC, from the Phase 3 NORA study for Zejula at the European Society for Medical Oncology, or ESMO, Virtual Plenary. The results showed that Zejula maintenance treatment using an individualized starting dose regimen provides a favorable OS trend irrespective of gBRCA mutation status compared with placebo, despite that 43% of patients in placebo arm received subsequently at least one dose of a PARP inhibitor post progression. MOS in the ITT population: 46.3 months for patients receiving Zejula versus 43.4 months for placebo group. MOS in gBRCA mutation subgroup: Not reached for patients receiving Zejula versus 47.6 months for placebo group. MOS in non-gBRCA mutation subgroup: 43.1 months for patients receiving Zejula versus 38.4 months for placebo group. No new safety signals were identified based on long-term follow-up. Median follow-up time for OS in Zejula and placebo arm was 45.7 and 44.5 months, respectively. Based on the OS analysis adjusted for subsequent PARP inhibitor therapy, mOS in the ITT population: 46.3 months for patients receiving Zejula versus 34.3 months for placebo group. MOS in gBRCA mutation subgroup: Not reached for patients receiving Zejula versus 42.1 months. MOS in non-gBRCA mutation subgroup: 43.1 months for patients receiving Zejula versus 32.6 months. The final prespecified OS analysis of the NORA study is expected in 2023.

16:08 EST First Bancorp declares quarterly dividend of 22c per share - The Board of Directors of First Bancorp has declared a cash dividend on its common stock of 22c per share payable on January 25, 2023 to shareholders of record as of December 31, 2022. The 22c dividend rate represents a 10% increase over the dividend rate of 20c paid in the comparable period of 2021.

16:08 EST Instructure acquires LearnPlatform - Instructure has completed the acquisition of LearnPlatform, a provider of technology that enables educators and their institutions to research, select and evaluate digital learning solutions. This platform aims to equip stakeholders across the educational landscape with real-time, meaningful insight into the effectiveness of their tools of choice. Based in North Carolina, the LearnPlatform team has approximately 70 employees. Since 2015, the company has equipped educators, leaders, policymakers and edtech partners with the tools to modernize their learning environments. The terms of the transaction were not disclosed.

16:06 EST AAR Corp. expands partnership with Ontic - AAR Corp. has expanded its partnership with Ontic by signing a military customer support distribution contract extension and a new long-term global commercial distribution agreement. Under the military customer support distribution contract extension, AAR will continue to provide supply chain solutions, including warehousing, logistics, and supply chain management, for Ontic's Cheltenham MRO. AAR will also continue to deliver global distribution services, including sales and international government customer support of electronic assemblies, flight control units, gyroscopes, and altimeters, for military operators. This comprehensive supply chain agreement primarily focuses on Western and European platforms and serves F-15, F-16, Hawk, and Sea King aircraft, which are experiencing an increased operational tempo.

16:03 EST AST SpaceMobile, NASA sign joint deal to improve spaceflight safety - AST SpaceMobile announced that its subsidiary, AST & Science, LLC, and NASA recently signed an agreement to formalize both organizations' dedication to maintaining and improving safety in the shared environment of space. The Space Act Agreement formalizes the prompt, detailed, and open sharing of information between AST SpaceMobile and NASA, enabling a deeper level of coordination, cooperation, and data sharing, defining the arrangement, responsibilities, and procedures for flight safety coordination. "Space is a shared resource that must remain safe and available to all. We are committed to using advanced technologies and best practices to protect this vital resource," said Raymond Sedwick, Chief Scientist of Space Systems at AST SpaceMobile. "This agreement formalizes a commitment between AST SpaceMobile and NASA to share information and help safeguard low Earth orbit."

16:00 EST Spire says FERC determines Spire STL Pipeline needed on permanent basis - The Federal Energy Regulatory Commission, or FERC, reissued a permanent Certificate of Public Convenience and Necessity for the Spire STL Pipeline, ensuring continued operation of the natural gas pipeline which delivers a critical source of energy for more than 650,000 homes and businesses in eastern Missouri, Spire announced. The permanent Certificate was approved by the FERC at today's agency meeting. This marks the fourth time the FERC has issued an operational certificate for the Spire STL Pipeline, in each instance determining the Pipeline is necessary, the company said. "We are pleased the FERC reached this decision after conducting a thorough review over the last 18 months following the DC Circuit court remand. This is in addition to the Commission's original review and approval of the Pipeline's certificate in 2018 plus three years of strong operational performance. There was substantial evidence in the record to confirm that the Pipeline has delivered strong performance, reduced costs and improved natural gas reliability across the St. Louis region - even during severe weather challenges like Winter Storm Uri in 2021," said Scott Smith, president of the Spire STL Pipeline.

14:13 EST Microsoft names Melanie Nakagawa as new Chief Sustainability Officer - In a blog post, Vice Chair and President of Microsoft Brad Smith said that Melanie Nakagawa will join Microsoft in January as the new Chief Sustainability Officer. Reporting directly to me as a Corporate Vice President, Nakagawa will partner with teams across Microsoft and take on the leadership role for company-wide environmental sustainability work. Nakagawa most recently served as Special Assistant to the President and Senior Director for Climate and Energy on the National Security Council at the White House, one of several roles she has held in the U.S. government. "Melanie joins Microsoft at a critical time. January will mark the third anniversary of our ambitious climate goals to be carbon negative by 2030 and remove our historical carbon emissions by 2050. While I'm pleased with our progress, we must accelerate our momentum and broaden even further our climate-related work," Smith said. Nakagawa will now lead the three-fold sustainability mission launched as a company in September at the U.N. General Assembly meetings. Reference Link

14:07 EST Sichuan Airlines selects Viasat In-Flight Connectivity for installation on A320s - Chinese air carrier Sichuan Airlines, Viasat (VSAT), and AeroSat Link Technology, a subsidiary of China Satellite Communications, announced the airline has selected Viasat's In-Flight Connectivity technology and equipment for installation on its Airbus (EADSY) A320 family of aircraft. "When in service, the Viasat terminal installed on the aircraft will connect to China Satcom's Ka-band satellite network and AeroSat Link's digital IFC service to provide IFC service to passengers and crew," Viasat stated. "Sichuan Airlines continuously seeks ways to enhance the onboard customer experience, and we are proud to be a part of the airline's pioneering effort to deliver high-quality, high-speed in-flight internet within China. Today's announcement is an exciting and meaningful milestone for our relationships with Sichuan Airlines and AeroSat Link, and we are thrilled to have Sichuan Airlines leading the way," said Don Buchman, VP and GM, Commercial Aviation, Viasat. Viasat, China Satcom and AeroSat Link will each maintain its own intellectual property and will operate its equipment using a multi-layered approach to network services, the company added.

13:41 EST Norwegian Cruise Line reports 9% reduction in shoreside roles - In a earlier regulatory filing, Norwegian Cruise Line said, "The Company is undergoing a broad and ongoing effort to improve operating efficiencies, including cost minimization initiatives, to strengthen the foundation for sustained, profitable growth. As part of this initiative, on December 14, 2022, the Company carried out a workforce reduction and rightsizing to better align the Company's workforce with its strategic priorities and prepare for its future growth, resulting in an approximately 9% reduction in current and planned shoreside roles."

13:16 EST Retractable Technologies reports stock price anomalies - Retractable Technologies issued a statement expressing the company's concern regarding stock price anomalies in its Common Stock and disclose actions taken to date: "Concerned about possible market manipulation, the Company engaged an independent highly reputable economic consulting firm in 2021 which analyzed millions of trades in the Company's stock in recent years. This in-depth analysis, costing the Company over $600 thousand, confirmed that there were statistically significant anomalies in the market's reaction to the Company's positive disclosures, meaning that the Company's stock price would often react negatively or in a statistically insignificant way following positive earnings reports and press releases. The Company's consultant presented its analysis to the U.S. Securities and Exchange Commission in March 2022. In late November 2022, the Commission informed the Company that it would not pursue the matter further from an enforcement perspective. In summary, the Company's management expresses its disappointment that the Company's stock price does not appear to correlate to the Company's actual value and advises its stockholders that an investment in the Company's stock is not likely to track the Company's operational performance based on historical data."

12:41 EST Sony says PS5 game 'Spider-Man 2' launches fall 2023 - Sony said in a PlayStation blog post that upcoming PlayStation 5 title "Marvel's Spider-Man 2" will launch in fall 2023. "Following the events of Marvel's Spider-Man and Marvel's Spider-Man: Miles Morales, the Spider-duo of Peter Parker and Miles Morales are back in the next blockbuster action chapter of the Marvel's Spider-Man series," the company said. "Much is still to be revealed about the game, and going off the quality of the past two titles, we're bound to be in for a fantastic new original Spider-Man adventure." The title was first announced in September 2021. Reference Link

12:20 EST Granite Ridge Resources Inc trading resumes

12:00 EST CI&T falls -10.8% - CI&T is down -10.8%, or -77c to $6.35.

12:00 EST Roblox falls -16.5% - Roblox is down -16.5%, or -$5.47 to $27.66.

12:00 EST Web Street, Inc. rises 10.7% - Web Street, Inc. is up 10.7%, or $3.31 to $34.29.

11:57 EST Ocugen human nuclear hormone receptor granted two orphan designations - Ocugen's Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3, or hNR2E3, was granted orphan designation as a treatment of Leber congenital amaurosis and as a treatment of Retinitis Pigmentosa, according to posts to the FDA website. Reference Link

11:46 EST ADS-TEC Energy announces strategic partnership with amperio - ADS-TEC Energy announced it has signed a master agreement with Cologne-based charging project management specialist amperio GmbH for the expansion of fast-charging infrastructure in Germany. Slate Asset Management, a global alternative investment platform targeting real assets, will provide the financing for the agreement. amperio will initially be installing 101 ADS-TEC Energy ChargePost systems, starting in 2023. To mark the start of the collaboration, the two companies are today installing and commissioning the first ADS-TEC Energy ChargePost charging system in Limburg an der Lahn. The charging station-installed in the public parking garage at the Limburg-Sud ICE station-will enable ultra-fast charging of e-vehicles for the "LahnStar" on-demand shuttle service, part of the city of Limburg public transportation system.

11:35 EST Krispy Kreme down 4% amid investor day presentations - Shares of Krispy Kreme are down 56c, or 4%, to $13.98. The company began its investor day meeting at 9 am ET and has presented FY22, FY23 and FY26 guidance during the presentations.

11:20 EST Lennar says inventory being 'carefully managed' - Says driving costs down as prices are reduced. Says cost reduction will improve lagging margins. Says reconsidered every land deal in pipeline. Says 'stopped the bleeding early". Says new land purchases will improve lagging margins. Says operating teams are looking for additional efficiencies.

11:02 EST Washington Trust increases quarterly dividend to 56c per share - The Board of Directors of Washington Trust Bancorp declared a quarterly dividend of 56c per share for the quarter ending December 31, 2022. This represents a two cents per share increase over the most recent quarterly dividend rate and the twelfth consecutive year with a dividend increase. The dividend will be paid January 6, 2023 to shareholders of record on January 3, 2023.

10:54 EST Granite Ridge Resources trading halted, news pending

10:03 EST Icosavax trading resumes

10:03 EST VerifyMe CEO 'pleased' with continued growth in agriculture, apparel in Q4 - VerifyMe together with its subsidiary PeriShip Global announced that it has received orders during the fourth quarter of more than $0.8M in VerifyMe technology-enabled product labels mainly from apparel and agriculture related clients. VerifyMe's CEO Patrick White commented, "We are pleased with the continued growth in the agriculture and apparel industries. We believe our strong fourth quarter orders reflect the quality and effectiveness of our brand protection and consumer engagement solutions allowing consumers to authenticate the product as genuine and download product certificates of analysis as well as other engagement functions directly to their mobile phone. These orders should enhance our fourth quarter results."

10:02 EST L3Harris announces delivery of first T7 explosive ordnance disposal robots to AF - L3Harris Technologies announced delivery of the first of more than 100 T7 explosive ordnance disposal robots to the U.S. Air Force as part of a contract supporting the USAF's global EOD mission. The initial four-robot delivery represents the first of 56 T7 robotic systems, support, maintenance and training provided under an $85M, 10-year, indefinite-delivery, indefinite-quantity contract awarded in September 2021. In May 2022 the USAF requested 51 additional T7 robots, for a total of 107 robots ordered to date.

10:00 EST Roblox falls -12.7% - Roblox is down -12.7%, or -$4.22 to $28.91.

10:00 EST MasterBrand falls -14.4% - MasterBrand is down -14.4%, or -$1.30 to $7.70.

10:00 EST Charles River rises 8.8% - Charles River is up 8.8%, or $18.96 to $233.29.

09:58 EST Icosavax trading halted, volatility trading pause

09:48 EST Vinco Ventures court-appointed CEO Ross Miller departs - Vinco Ventures has completed the first stage of a planned transition that positions the company with a runway to focus on revenues and profitability. As such, the Board of Directors announces court-appointed CEO Ross Miller and his team, including Gabe Hunterton, President, have departed the company effective immediately. Vinco Ventures is set to appoint a new permanent CEO with leadership experience at media companies and entertainment brands. The candidate was subject to an extended vetting process. Chairman of the Board, Rod Vanderbilt, will assume the role of Executive Chairman and lead all Vinco teams on a day-to-day basis.

09:47 EST Alight falls -8.9% - Alight is down -8.9%, or -80c to $8.18.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares rises 6.0% - Direxion Daily Semiconductor Bear 3X Shares is up 6.0%, or $1.87 to $33.05.

09:47 EST TAL Education rises 7.0% - TAL Education is up 7.0%, or 42c to $6.41.

09:34 EST MetLife Investment Management to acquire Affirmative Investment Management - MetLife Investment Management, the institutional asset management business of MetLife (MET), announced that it has entered into a definitive agreement to acquire Affirmative Investment Management, or AIM, a specialist global environmental, social and corporate governance, or ESG, impact fixed income investment manager. As of June 30, 2022, AIM's assets under management were $1.01B. The acquisition is subject to customary closing conditions, including regulatory approval. "By combining AIM's expertise with MIM's commitment to sustainable investing, we will be even better positioned to provide comprehensive insight and counsel to clients and consultants on ESG considerations. MIM will maintain its fundamental investment processes, and AIM brings us additional capabilities to evaluate sustainability and risk considerations across our core competencies in public fixed income, private fixed income and real estate," said Steven Goulart, president of MIM and executive vice president and chief investment officer for MetLife.

09:34 EST Walmart announces drone delivery now available in Phoenix market - Walmart's drone delivery service is now available for select customers in the Phoenix market. The new delivery option will be fulfilled from four stores, making it easier than ever for customers to grab those last-minute gifts.

09:30 EST Performance Shipping announces delivery of M/T P. Long Beach - Performance Shipping announced that, through a separate wholly-owned subsidiary, it has taken delivery of the M/T P. Long Beach, a 2013-built LR2 Aframax oil product tanker vessel of 105,408 dwt that the Company entered into an agreement to purchase in November 2022. As previously announced, the M/T P. Long Beach was acquired for a total purchase price of US$43.75 million and partially financed through the recently announced term loan facility with Alpha Bank S.A. The M/T P. Long Beach is equipped with an eco-electronic engine and fitted with a ballast water treatment system. The vessel is the fourth vessel delivered to the Company during the course of this year, bringing the Company's current fleet to a total of eight Aframax tanker vessels.

09:29 EST Walmart announces drone delivery now available in Dallas area - Walmart's drone delivery service is now available for select customers in the Dallas-area. The new delivery option will be fulfilled from 11 stores, making it easier than ever for customers to grab those last-minute gifts. No assistance from Rudolph needed.

09:28 EST Walmart announces drone delivery now available in Tampa, Orlando areas - Walmart's drone delivery service is now available for select customers in the Tampa and Orlando areas. The new delivery option will be fulfilled from 7 stores, making it easier than ever for customers to grab those last-minute gifts. No assistance from Rudolph needed.

09:25 EST Willdan Group awarded 45M contract by Trinidad School District - Willdan Group announced that it has been awarded a $5M contract by Trinidad School District to provide energy and infrastructure renovations for Trinidad High School. This contract includes energy efficiency upgrades to the school's HVAC, ventilation, and lighting systems, as well as a roof replacement and plumbing equipment installation across three campus buildings. Willdan previously developed the master plan for the District and completed infrastructure upgrades for Trinidad Middle School.

09:23 EST Patterson Companies appoints Kevin Barry as CFO, Kevin Pohlman COO - Patterson Companies announced enhancements to its executive leadership team to further support the execution of its strategy. Kevin Barry, most recently the company's interim CFO, has been named CFO, and Kevin Pohlman, most recently president of Patterson Animal Health, has been named COO. As COO, Kevin Pohlman will be focused on optimizing performance and driving efficiency across Patterson.

09:23 EST Blink Charging to unveil suite of new products at CES 2023 - Blink Charging announced it will unveil five new products at the annual Consumer Electronics Show, CES, taking place in Las Vegas next month. Electric vehicle penetration is at an all-time high, with global sales in the first quarter of this year up 75% from the same period in 2021, and Blink Charging is positioned to play a leading role in building out the EV charging network needed to fuel this new electrified fleet. Another major step forward as the Company expands its global footprint, these new products are designed to serve the increasing demands of EV markets across the U.S, Europe, Asia and Latin America, as well as to offer greater options for advertisers and marketers looking to tap into the growing EV charging ecosystem. This announcement comes on the heels of several exciting developments at Blink, including the showcase of three of its newest charging products - the MQ 200, HQ 200 and 30kW DC Fast Charger - at the LA Auto Show in November and the release of the entirely rebuilt Blink Network and Blink Charging Mobile App in October.

09:22 EST National Instruments appoints Daniel Berenbaum as CFO - National Instruments (NATI) announced that Daniel Berenbaum has been appointed executive vice president, chief financial officer and treasurer, effective January 9, 2023. Berenbaum will succeed Karen Rapp in her role as CFO, who announced her retirement last quarter. Rapp will continue in a strategic advisory role to ensure an orderly transition. Berenbaum is currently the vice president, finance and global operations controller for Micron (MU) where he is responsible for all financial aspects of the company's manufacturing, global supply chain, and IT. He has a proven track record of delivering operational efficiency and profitable growth.

09:21 EST EzFill to launch streamlined payment system - EzFill announced that it is launching EzFill Pay, a new simplified way for drivers to order and pay for gas. The new payment system will enable EzFill to open "pop-up" gas stations at parking lot locations in all of its service areas. EzFill Pay is a streamlined payment system which will allow drivers the ability to pay for fuel without having to first download the app. EzFill's Pop-up gas stations will be utilized as a marketing tool and an innovative way to bring gas to customers in South Florida. EzFill's first pop-up took place yesterday at an employee appreciation event for Florida based real estate developer, Turnberry. EzFill expects to launch its first public pop-ups at three parking lots in downtown Miami, right across from the home arena of the Miami Heat, where most gas stations have closed and few gas stations remain. Mike McConnell, EzFill Chief Executive Officer, commented, "The pop-up industry has become an essential element of consumer marketing, with research from the American Marketing Association valuing the industry at $50 billion and growing. We believe that our pop-up stations will be a cost-effective opportunity for us to get our brand in front of the actual fuel purchasers, in a way that highlights the convenience and efficiency of the EzFill service. The simplified payment system will be seamless and hassle-free, illustrating the cutting-edge nature of EzFill's user technology. We look forward to the success of our first pop-ups and similar ventures in the future."

09:20 EST Iveda Solutions launches national investor awareness program with Acorn - Iveda has launched a full-scale, national investor awareness program through a proprietary multi-layered system being executed by Acorn Management Partners. Together, the organizations will execute a program that works to 1) generate additional awareness of and knowledge about Iveda and its achievement of key financial goals over time; 2) drive long-term investors through financial professionals to Iveda; and 3) create meaningful relationships with financial professionals in order to increase the shareholder base and create a truly sophisticated market. "Since Iveda's IPO in April of this year, we've been on a rapid and exciting growth trajectory; one that we anticipate will continue climbing as cities and communities around the world look to make the leap to smart city status," added David Ly, CEO and founder of Iveda. "In partnering with Acorn Management Partners, we're eager to continue connecting with investors in the space and to bring Iveda's AI-powered video search and surveillance technology to hospitals, campuses, and municipalities across the globe."

09:17 EST AssetMark Financial completes acquisition of Adhesion Wealth - AssetMark announced the completion of its acquisition of Adhesion Wealth, a leading provider of wealth management technology solutions to RIAs, RIA enterprises, TAMPs and asset managers. Adhesion is the industry's second-largest model marketplace with over 400 asset managers. The platform provides its clients with outsourced overlay portfolio management services, client engagement technologies, and tailored managed account solutions for TAMPs and RIA enterprises. For the foreseeable future, Adhesion will continue to operate commercially as a standalone business and will maintain its brand identity. AssetMark acquired total billable assets of $7.3B as of November 30, 2022 and paid $46M plus transaction costs and contingent payments.

09:15 EST AgriFORCE begins commercialization of UN(THINK) Awakened Flour - AgriFORCE announced the commercialization of UN(THINK) Awakened Flour following the successful completion of the scaled up batch trial. Commercialization will follow at the beginning of 2023 and focus on bakeries in Canada and the USA, followed by a direct-to-consumer launch. As announced earlier this year, Awakened Flour is a "better for you" flour that uses a 100% natural patent-pending process to create a gently germinated flour that is more nutritious, easier to digest, and better tasting with 2 times the protein of regular wheat flour . AgriFORCE's highly precise sprouting process increases the bioavailability of vitamins and minerals, allowing them to be absorbed by the body, while changing the total amount of fiber in whole grains, helping to improve gut health. Production is currently based in Saskatoon, Saskatchewan, Canada, one of the world's best and largest grain producing regions. UN(THINK) Foods has secured strategic partnerships with local non-GMO suppliers and specialty milling partners who bring their expertise and care to the products.

09:13 EST Super Group comments on recent ant-dilutive measures - Super Group commented on the impact of the previously announced company public warrant exchange, the cancellation of private warrants and earnout shares waiver, which jointly remove potential issuance of approximately 78.8M company ordinary shares, lowering the company's potential fully diluted share count by 13.6% to approximately 502.41 million. Neal Menashe, CEO, and Richard Hasson, president and COO, jointly stated, "Today's efforts simplify our capital structure and reduce the prospect of potential future dilution. As a team, together with our sponsors, who agreed to cancel their private warrants, and our original shareholders, who waived their rights to earn-out shares, we remain committed to our long-term vision and to taking proactive steps to create value for investors and greater certainty around our capital structure."

09:12 EST Evergy to transfer listing to Nasdaq from NYSE - Evergy announced it will transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market, effective as of the opening of trading on Wednesday, December 28. The last day of trading on the NYSE will be Tuesday, December 27. Evergy's common stock will continue to trade under the ticker symbol (EVRG).

09:10 EST BK Technologies receives $500,000 purchase order from reseller - BK Technologies announced that it has received a purchased order in the amount of $500,000 from one of its resellers, for the company's BKR 5000 portable communications technology. The order comes from the Santa Barbara County Fire Department in California as part of the department's lifecycle replacement program.

09:09 EST Viveve completes 12-month post-treatment follow-up visits in PURSUIT trial - Viveve announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence, or SUI, in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month follow-up visits. A 17.6% loss-to-follow-up occurred, which is within the range anticipated for the trial. Upon completion of clinical data monitoring and analyses in the coming weeks, the company expects to present topline primary efficacy results from the PURSUIT trial in January 2023. If positive, the results may support a marketing application for a potential new SUI indication for Viveve's dual-energy, noninvasive, single-session treatment in the U.S.

09:07 EST WisdomTree launches U.S. Quality Growth Fund - WisdomTree announced the launch of the WisdomTree U.S. Quality Growth Fund on the New York Stock Exchange. QGRW seeks to track the price and yield performance, before fees and expenses, of the WisdomTree U.S. Quality Growth Index and has an expense ratio of 0.28%. "Growth investors prevailed for much of the last decade and seemingly received extra focus with the pandemic that catalyzed high growth stocks that facilitated the work from home environment. However, many of these same high growth companies - that have yet to achieve profitability-struggle now to raise fresh capital at much lower multiples or with higher financing costs on their debt," said Jeremy Schwartz, WisdomTree's Global Chief Investment Officer. "QGRW was a strategy built for the long run and identifies companies with high-quality and profitability metrics combined with good growth potential, which is especially important for the next cycle when growth stocks turn in favor."

09:07 EST Ericsson provides long-term targets and strategy on 2022 Capital Markets Day - Ericsson is hosting a Capital Markets Day to share insights on the company's strategic priorities. Ericsson's strategy is to leverage leadership in mobile networks, drive focused expansion in enterprise, lead the industry with critical innovations, and capture strategic business opportunities. Ericsson's Enterprise strategy is organized around two pillars: Enterprise Wireless Solutions and Global Network Platform. In Networks, Ericsson expects to expand its global footprint and enhance gross income through continued investments in technology. Ericsson is implementing a revised strategy for profitability in the segment Cloud Software and Services. The target is to reach break-even in full-year 2023 with gradual improvements towards long-term sustainable profitability. Overall RAN market is expected to be flat with growth of 11% p.a. in the 5G RAN market over the next 3 years. The 5G RAN market is expected to grow by over 11% per annum over the next three years. Ericsson remains committed to growing its 39% RAN market share outside of China by 1% per year and increasing gross profit. After record capex levels in North America in 2022, build-out is expected to normalize in 2023, beginning in Q4 of this year. At the same time, revenues from share gains in other markets are expected to accelerate during Q4 and into 2023. While these market share gains contribute to gross profit, they will be margin dilutive. Looking to 2024 and beyond, underlying traffic development is expected to continue developing favorably, giving confidence on the longer-term development of investments. Ericsson confirms long-term target of EBITA margin of 15%-18% and expects to reach the lower end by 2024. This will offset headwinds such as business mix changes and inflation. There is significant growth potential in IPR revenues over the coming 18-24 months. Aims at generating Free Cash Flow before M&A of 9%-12% of sales. Remains committed to be Net Zero within its own operations by 2030 and to reach Net Zero across the value chain by 2040. Ericsson is introducing near-term capital allocation priorities with a central focus on generating free cash flow in line with the target of 9-12% free cash flow before M&A over net sales, deploying our capital wisely for maximum value creation, while safeguarding balance sheet strength. M&A will be limited to bolt-on acquisitions with attractive returns and clear strategic fit. Further, Ericsson targets a stable to progressive dividend with a policy based on earnings, business outlook and financial position.

09:05 EST SenesTech: ContraPest to be deployed at Los Angeles Zoo - SenesTech announced that the City of Los Angeles has ordered and plans to deploy ContraPest broadly at the Los Angeles Zoo, one of the top 10 in the nation. "The LA Zoo started with a deployment of 17 bait stations. Once they were confident in ContraPest, we worked with them to develop a deployment plan which is expected to exceed 250 bait stations. We now move into deployment support with them, providing training and consultation as needed," said Nicole Williams, SenesTech's Chief Strategy Officer. "We will also be using this as a further example of ContraPest's use in integrated pest management as we market to other parts of the City of Los Angeles and beyond."

09:04 EST Uber, Cartken partner for sidewalk robot deliveries - Uber Technologies and Cartken announced a new partnership for food deliveries via automated robots in Miami, Florida. Uber Eats consumers in Miami will have the opportunity to have orders delivered by Cartken's self-driving robot. Uber and Cartken will begin operating with select merchants in the Dadeland area of Miami-Dade County with plans to expand in Miami-Dade and to additional cities in 2023. Cartken's AI-powered sidewalk delivery robots currently are used for neighborhood food and grocery delivery, campus meal delivery and curbside pickup across the country. Uber Eats will be its first formal partnership with a global on-demand delivery app beyond college campuses.

09:03 EST Mullen receives purchase order for 6,000 EV cargo vans from Randy Marion - Mullen Automotive announces a purchase order for 6,000 Class 1 EV cargo vans from Randy Marion Isuzu,, a member of the Randy Marion Automotive Group. The firm order agreement is valued at approximately $200 million. RMA is one of the largest and most respected commercial vehicle dealer groups in the U.S. Randy Marion Isuzu, a division of RMA, has committed to purchase 6,000 Class 1 EV cargo vans from Mullen Automotive. Mullen recently announced RMA as its first commercial dealer partner to offer sales, service and parts for Mullen Automotive's commercial vehicle lineup. "We see a tremendous opportunity with the Mullen commercial portfolio, and the launch of the commercial van could not come at a better time," said Randy Marion, CEO and founder of RMA. "There's significant pent-up customer demand for Mullen to fulfill. I have many customers looking at me to find product for their companies."

09:02 EST Broadcom announces availability of CA 1 Flexible Storage soution - Broadcom announced the availability of a new solution that enables enterprises to store their mainframe data anywhere they choose, including the Cloud. Broadcom's CA 1 Flexible Storage solution provides secure, cost-effective mainframe data storage options for hybrid IT environments, making it possible for customers to achieve dramatic cost savings and protect against ransomware.

08:55 EST Mullen Automotive trading halted, news pending

08:50 EST Glimpse Group's Sector 5 Digital completes contract for Mavenir VCEP - The Glimpse Group announced that its subsidiary company Sector 5 Digital completed a mid-six figure contract for the creation of a virtual customer experience platform for Mavenir, a cloud native 5G network software provider.S5D created the Mavenir Virtual Customer Experience Platform, a browser-based digital storytelling tool that invites customers to explore a variety of hypothetical "day in the life" scenarios: Consumer, Enterprise, and Industry 4.0 with each scenario including their end-to-end network architectures and data flows. Users were also able to visit the Mavenir Virtual Demo Lab portion of the experience and interact with the scenario equipment in addition to watching product demos.

08:48 EST EU passenger car registrations up 16.3% in November - In November, the EU new passenger car market posted "another strong uplift" of 16.3%, the fourth in a row this year, said the European Automobile Manufacturers Association. Nevertheless - with 829,527 units sold - last month's volumes remained well below the pre-pandemic levels of November 2019, when 1 million cars were registered, the group added. Eleven months into 2022, new passenger car registrations across the European Union were 6.1% lower compared to the same period last year, the group said. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY).

08:46 EST Eskay Mining expands TV-Jeff precious metal-rich VMS system - Eskay Mining expanded the TV-Jeff precious metal-rich volcanogenic massive sulfide mineralized corridor with new discoveries north of the Jeff deposit and in proximity to the TV deposit. Recent data analysis also points to a link between the TV-Jeff system on the east side of the Eskay Anticline with the Eskay Creek-SIB-Lulu system on the west. Assays from the Scarlet Ridge, Scarlet Valley, Scarlet Knob and Tarn Lake are awaited from the laboratory. Highlights: The first assays to return from holes completed in areas in proximity to the TV deposit have yielded strong results including: 3.36 gpt Au and 109.50 gpt Au over 2.00m within 1.14 gpt Au and 30.58 gpt Ag over 30.56m in hole TV22-97; 1.03 gpt Au and 173.12 gpt Ag over 5.65m within 1.28 gpt Au and 87.92 gpt Ag over 14.95m in hole TV22-109. Wide-spaced drilling approximately 800m north of Jeff encountered a new zone of mineralization that yields high-grade Au-Ag results, some within longer intervals of lower grade mineralization. Results include: 15.44 gpt Au and 28.20 gpt Ag over 1.59m within 1.06 gpt Au and 2.24 gpt Ag over 43.96m in hole J22-89; 8.50 gpt Au and 11.88 gpt Ag over 1.75m in hole J22-97; 10.75 gpt Au and 31.00 gpt Ag over 0.60m within 1.03 gpt Au and 6.20 gpt Ag over 7.85m in hole J22-98. VMS mineralization along the TV-Jeff corridor, hosted by Lower Hazleton Group volcanic rocks, is now confirmed over a strike length of 3.1 km. Eskay's geologic team has recently gathered strong evidence pointing to a physical connection between the TV-Jeff VMS system on the east side of the Eskay Anticline with the Eskay Creek-SIB-Lulu system on the west thus opening up considerable opportunity for further exploration discoveries.

08:43 EST Edgio cuts 10% of workforce as part of restructuring - In a regulatory filing last night, Edgio disclosed that on December 13, the board of directors of the company approved a restructuring plan in order to reduce its operating costs as "part of its transformational initiative to optimize its business model and increase efficiencies." The restructuring plan is anticipated to entail a reduction in force of approximately 95 employees, or approximately 10% of the company's global workforce, to be implemented through the second quarter of 2023. The company estimates that restructuring plan charges will be approximately $2.6M and will be recorded as restructuring expenses which consist of one-time severance charges and continuation of health benefits. The foregoing estimated charges will be cash expenditures. The company anticipates it will generate approximately $14.0M in net annual savings. In the same filing, Edgio disclosed that on December 14, Eric Armstrong and the company entered into a separation and release agreement, whereby Mr. Armstrong will leave his position as the company's Growth Officer on December 31, 2022. Armstrong's duties will be assumed by Bob Lyons, the company's Chief Executive Officer, while the company "continues to explore and evaluate the needs and future leadership of the sales organization," the filing stated.

08:40 EST Emcore announces sale, leaseback of Tinley Park facility - Emcore Corporation announced that pursuant to a Purchase and Sale Agreement entered into on November 1, 2022, it has completed the sale and leaseback of its Tinley Park, IL facility, generating $10.3M in net cash proceeds.

08:39 EST eMagin receives $1.7M order from Collins Aerospace - eMagin Corporation announced it has received an order of approximately $1.7M for high-brightness OLED microdisplays from Collins Aerospace for its F-35 Helmet Mounted Display System, HMDS. "Our OLED displays are recognized as the best fit for critical military applications such as the F-35 Helmet Mounted Display Systems supplied by Collins Elbit Vision Systems," said eMagin CEO Andrew Sculley. "The extensive functionality of the HMDS and the extreme conditions in which it must operate require our unique, high-brightness OLED display technology. This significant purchase order is another testament to the value we bring to mission-critical applications, and we are proud of our long and successful history of working closely with Collins Aerospace on several programs."

08:38 EST Altus Group appoints Pawan Chhabra as CFO - Altus Group announced the appointment of Pawan Chhabra as CFO effective January 1, 2023. Pawan joins Altus from ADP, where he held several senior finance roles since 2011, most recently serving as the CFO of Worldwide Sales and Marketing.

08:38 EST First Solar enters agreement to supply 1.6 GW of its modules to National Grid - First Solar (FSLR) has entered into an agreement to supply 1.6 gigawatts, GW, DC of its high-performance, responsibly produced Series 7 thin film solar modules to National Grid Renewables, a division of National Grid ( NGG). The deal was booked prior to the release of First Solar's Q3 2022 earnings in October and the modules are scheduled to be delivered in 2026 and 2027. This latest order expands First Solar's relationship with National Grid Renewables to over 4 GWDC, with an earlier agreement for 2 GWDC of modules announced in June 2022. "We are pleased to further expand both our partnership with First Solar and our commitment to using responsibly produced solar technology to power our near-term project pipeline," said Andy Cukurs, chief operating officer, National Grid Renewables. "These modules will be deployed in projects throughout the United States, bringing clean energy and economic benefits to communities across the country."

08:36 EST Rumble announces partnership with Power Slap - Rumbl announced a partnership with Power Slap, the world's premier slap fighting organization, The partnership will include an all-new exclusive show on Rumble focused on the sport and featuring Dana White, along with Power Slap starting a new Rumble channel and Locals' community. "This partnership with Power Slap is exactly the type of strategic investment that helps us grow and diversify our content library," said Rumble Chairman and CEO Chris Pavlovski. "When Dana is excited about something like Power Slap, we listen," Pavlovski continued. "He is a proven visionary in this space, and we can't wait to be a part of this amazing journey with Power Slap."

08:35 EST Tarsus Pharmaceuticals announces data from Phase 1b Callisto trial - Tarsus Pharmaceuticals announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial. The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease. The Callisto trial was a randomized, double-blind, single- and multiple-ascending dose study that evaluated the safety, tolerability, food-effect, and pharmacokinetics of TP-05 in healthy subjects. Results from the trial showed that TP-05 was well tolerated with no dose-related or drug-related serious adverse events. Pharmacokinetic data from the trial demonstrated rapid absorption and an extended half-life of TP-05 that potentially supports a monthly, or less frequent therapy regimen, supporting its potential as a convenient, rapid onset, prophylactic therapy for Lyme disease. Additionally, exploratory ex-vivo tick kill modeling utilizing serum from TP-05-treated subjects demonstrated potent, rapid killing of adult and nymph ticks. Tarsus also announced the enrollment of the first patient in the Carpo trial, evaluating TP-05 for the potential prevention of Lyme disease in humans. The Carpo trial is a randomized, double-blind trial that will evaluate the efficacy of TP-05 in killing sterile, non-disease carrying ticks after they have attached to the skin of healthy volunteers, as well as confirm the safety, tolerability, and blood concentration of TP-05. TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-CI channels. TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission.

08:33 EST Surgalign reports 100th case completed using Cortera system - Surgalign Holdings announced a key milestone for its recently introduced posterior fixation platform - the Cortera Spinal Fixation System. Surgalign received FDA 510(k) in August 2022 and Cortera and was introduced in a limited market release shortly thereafter. In a little over three months, the Company has successfully penetrated target markets and today announced the completion of the 100th case utilizing this new flagship pedicle screw system. During this initial market release, Surgalign's goal has been to collect clinical and design feedback on the system from a wide range of spine surgeons, representing the user needs and preferences of the broader market. Efforts are now underway to secure additional products and the Company intends to ramp up commercialization in the first half of 2023 as it looks to grow its market share in the estimated $2.2B US posterior fixation market.

08:31 EST Vivid Seats announces opening of Chicago headquarters - Vivid Seats announced it has opened its new corporate headquarters in the historic Marshall Field building at 24 E. Washington Street in downtown Chicago, where it has been headquartered since 2001.

08:30 EST Agilysys announces agreement with Marriott to deploy PMS software - Agilysys (AGYS) announced an agreement with Marriott (MAR) to deploy its cloud-native property management system, or PMS, software across Marriott's United States and Canada luxury, premium and select service hotels over the coming years. Agilysys offers hospitality-focused innovation, the ability to provide diverse capabilities across different types of properties, and cloud-native technology that simplifies employee operations and enhances guest experiences. Agilysys and Marriott will work together to closely align resources and activation plans before beginning to replace multiple proprietary property management systems that are currently in use.

08:28 EST Roblox reports November DAUs 56.7M, up 15% - Reports November hours engaged 3.9B, up 10%. Reports November revenue $190M-$193M. Reports November bookings $222M-$225M. Reports November average bookings per daily active user $3.92-$3.97.

08:26 EST Titan Aircraft, Georgian Airlines announce long-term agreement for a Boeing 737 - Titan Aircraft Investments announced the placement of one Boeing (BA) 737-800SF converted freighter on long-term dry lease with Georgian Airlines to support its network. Titan Aviation Holdings, a subsidiary of Atlas Air Worldwide Holdings (AAWW), will manage this asset. "We are delighted to welcome Georgian Airlines and appreciate their trust in Titan as we support their growing business," said Michael Steen, President and Chief Executive Officer of Titan Aviation Holdings and Chief Commercial Officer of Atlas Air Worldwide.

08:26 EST Royalty Pharma announces expansion of senior leadership team - Royalty Pharma announced the expansion of its senior leadership team. The following promotions are effective January 1, 2023, and each individual will join the Senior Leadership Committee: Sara Klymkowsky will be promoted to Senior Vice President, Research & Investments. Sara has been an integral member of the Research & Investments team since joining Royalty Pharma in 2012. She has played a key role in executing many of Royalty Pharma's most important transactions, including investments in the Vertex cystic fibrosis franchise, Tysabri and Trelegy. Brienne Kugler will be promoted to Senior Vice President, Research & Investments. Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014. She has played a major role in executing many of Royalty Pharma's most important transactions, including multiple Biohaven investments, Tremfya and Evrysdi. Alessandra Sassun will be promoted to Senior Vice President, Head of Human Capital. Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma's human resource planning, professional development and performance management.

08:24 EST MCI Onehealth's Khure enters partnership with U.S. nephrology practice - MCI Onehealth Technologies provides an update on its subsidiary Khure Health's expansion into the American healthcare market. Khure Health is now offering its AI-enabled clinical intelligence technology and services for rare and complex diseases to healthcare practitioners in the United States. Khure Health has recently signed its first US contract with one of the largest private nephrology practices in the southern United States comprising over 25 outpatient clinics and more than 40 dialysis centers. The agreement has already begun to drive revenue in Q4 2022 via an associated agreement with a large established top 10 global pharmaceutical company. The agreement will allow Khure Health to showcase its clinical data insights capabilities in a specialist healthcare setting and will enable further clinical research and data insights partnerships with life sciences companies

08:22 EST Surge Copper announces assay results from Ootsa Property - Surge Copper announced complete assay results for 1 hole from the first phase of the Company's 2022 regional exploration program which was focused on target drilling within the 100% owned Ootsa Property in central British Columbia. Highlights: Hole BJ22-01 at the Blackjack Target tested a large ZTEM geophysical anomaly and has discovered a wide zone of silver-gold-zinc-lead mineralization in addition to 3 individual high-grade silver veins. Results include 66 metres grading 71.3 g/t silver including 46 metres grading 99.4 g/t silver with higher grade intercepts returning: 1430 g/t silver over 2 metres; 346 g/t silver over 2 metres; 180 g/t silver over 2 metres. The Blackjack Target represents a very large and highly altered intrusive centre that is highly prospective for precious metal mineralization and wide open for further expansion and discovery; Results for 30 additional drill holes from the Ootsa and Berg 2022 regional exploration program are pending. Assay results have been received for BJ22-01 at the Blackjack Target located approximately 4 kilometres east of the Seel porphyry deposit on the Ootsa Property.

08:19 EST Univar and Kalsec expand distribution partnership for ingredient solutions - Univar subsidiary Univar B.V. and Kalsec, a natural ingredient solution provider for the food and beverage industry, have reached an exclusive agreement for Univar Solutions to distribute Kalsec's natural taste & sensory, colors, and food protection ingredient solutions for savory applications in the U.K. and Ireland.

08:18 EST Aziyo Biologics announces funding of additional $4M term loan - Aziyo Biologics (AZYO) received an additional $4M term loan from SWK Holdings Corporation (SWKH). The additional $4M term loan is the second tranche under an existing aggregate $25M credit facility. The initial $21M term loan under the facility was funded in August 2022. The additional debt financing follows Aziyo's recently closed $11.2M public offering of common stock in December 2022, resulting in a combined aggregate amount of $15.2M in gross proceeds from these two financings. The Company plans to use the proceeds to expand its product development and clinical research activities, hire additional sales personnel to coincide with product launches and to fund working capital and other general corporate purposes.

08:17 EST Harsco signs extension contract with Compania Siderurgica Huachipato - Harsco announced that its Harsco Environmental division has extended its contract with Compania Siderurgica Huachipato, CSH, Chile's largest steelmaker. Harsco Environmental signed a 5-year renewal contract with an estimated revenue of $28M to provide services at the company's site in Chile. Through this renewal, Harsco Environmental will focus on maintaining operational excellence, integrating key performance indicators, and reinforcing vital operational activities. The scope of work will remain the same as the previous contract between Harsco Environmental and CSH, with melt shop cleaning, wrecking, scrap chute loading, scrap handling, oxy cutting, scrap shearing, metallic recovery, and slag sales services.

08:16 EST M3-Brigade Acquisition III Corp., Greenfire Resources announce combination - Greenfire Resources, a Calgary-based energy company focused on the sustainable production and development of thermal energy resources from the Athabasca region of Alberta, Canada, and M3-Brigade Acquisition III Corp., announced that they have entered into a definitive agreement for a business combination that values Greenfire at $950M. The closing of the Business Combination is expected to occur in Q2 2023 and upon closing Greenfire Resources Ltd. will become the parent of both Greenfire and MSBC. GRL is a newly created corporation incorporated under the laws of the province of Alberta to participate in the Business Combination. Following completion of the Business Combination, GRL is expected to continue to be managed by Greenfire's current executive team. The combined company will remain focused on optimizing Greenfire's existing production and facilities, with the objective of further enhancing its cash operating netbacks and free cash flow per barrel, with the intention to return capital to its stakeholders over time.

08:15 EST Stran & Company announces Nasdaq ticker symbol change - Stran & Company announced that the Company's common stock will begin trading on Nasdaq under the ticker symbol "SWAG" on December 16, 2022. This ticker symbol will replace the Company's current ticker symbol for its common stock, "STRN". Additionally, the Company's publicly traded warrants to purchase common stock will begin trading under the ticker symbol "SWAGW" on December 16, 2022. This ticker symbol will replace the Company's current ticker symbol for its publicly traded warrants, "STRNW".

08:14 EST Grainger names Nancy Berardinelli-Krantz as Chief Legal Officer - Grainger (GWW) announced it has appointed Nancy Berardinelli-Krantz as Senior Vice President and Chief Legal Officer, effective Jan. 30, 2023. Berardinelli-Krantz will succeed John Howard who will retire from the company in July 2023 after 23 years of service. Berardinelli-Krantz joins Grainger from Eaton (ETN), where she is Senior Vice President and Deputy Chief Legal Officer.

08:12 EST ProSomnus announces Medicare reimbursement for ProSomnus EVO device - ProSomnus announced that its ProSomnus EVO Sleep and Snore Device now qualifies for Medicare reimbursement. The Pricing, Data Analysis, and Coding Contractor has reviewed and verified the device for the Healthcare Common Procedure Coding System code E0486. Medicare beneficiaries account for an estimated 20% of people in the United States with OSA. The ProSomnus EVO is a precision OAT medical device specifically engineered to meet Centers for Medicare Services coding guidelines, offering Medicare beneficiaries a non-invasive, comfortable, easy-to-use, and effective alternative to CPAP machines, surgical procedures, and legacy dental products. Per Medicare coding guidelines, the ProSomnus EVO device repositions and stabilizes the patient's jaw during sleep, increasing pharyngeal space and reducing the risk of upper airway collapse. "With Medicare coding verification, the ProSomnus EVO offers healthcare providers and their Medicare beneficiary patients a comfortable, effective and reimbursable treatment option for OSA that addresses many of the limitations of dental product and CPAP therapies," said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus. "Achieving Medicare coding verification for the ProSomnus EVO enhances our momentum as we expand availability of precision OAT to even more patients, thereby increasing adoption and creating better patient outcomes when treating OSA, a disease state impacting 74 million Americans today."

08:12 EST Williams to acquire MountainWest from Southwest Gas for $1.5B - Williams (WMB) announced that it has reached an agreement to acquire MountainWest from Southwest Gas (SWX), in a transaction including $1.07B of cash and $0.43B of assumed debt, for an enterprise value of $1.5B. MountainWest comprises roughly 2,000-miles of interstate natural gas pipeline systems primarily located across Utah, Wyoming and Colorado, totaling approximately 8 Bcf/d of transmission capacity. MountainWest also holds 56 Bcf of total storage capacity, including the Clay Basin underground storage reservoir, providing valuable service to western markets. The acquisition price represents an approximate 8x estimated 2023 EBITDA multiple. The transaction is expected to close in 2023, following satisfaction of customary closing conditions, including regulatory approvals and the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

08:11 EST Rigel Pharmaceuticals doses first patient in Phase 1b study of R289 - Rigel Pharmaceuticals announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk myelodysplastic syndromes who are refractory or resistant to prior therapies. Rigel's open-label, Phase 1b study of R289 is expected to enroll approximately 22 patients with lower-risk MDS who are refractory or resistant to prior therapies. The primary objective of the study is safety, with secondary and exploratory objectives to assess preliminary efficacy and characterize the pharmacokinetic and pharmacodynamic profile of R289. The safety and efficacy data from this Phase 1b study, along with the safety and PK/PD data from the completed first-in-human study in heathy volunteers, are intended to be used to determine the recommended Phase 2 dose for future clinical development of R289 targeting lower-risk MDS.

08:10 EST Wolfspeed announces long-term Silicon Carbide wafer supply agreement - Wolfspeed announced the expansion of an existing multi-year, long-term Silicon Carbide wafer supply agreement, now worth approximately $225M, with a power device company. The expanded agreement calls for Wolfspeed to supply the company with 150 mm Silicon Carbide bare and epitaxial wafers, reinforcing the company's vision for an industry-wide transition from silicon to Silicon Carbide semiconductor power devices.

08:09 EST Cadence Bank announces new 10M share repurchase program - Cadence Bank's Board of Directors authorized a new share repurchase program allowing the company to purchase up to an aggregate of 10M shares of Cadence's common stock. Subject to the approval of the Federal Deposit Insurance Corporation, this new share repurchase program will be effective on January 3, 2023 and will expire on December 29, 2023. Cadence has repurchased 6.1M shares of Cadence common stock authorized under its current share repurchase program, which expires December 30, 2022.

08:08 EST Kintara Therapeutics' VAL-083 granted Orphan Drug Designation for DIPG - Kintara Therapeutics has received Orphan Drug Designation from the FDA for VAL-083 for the treatment of diffuse intrinsic pontine glioma - DIPG -, a rare and highly-aggressive childhood brain cancer.

08:07 EST Enterprise Products operating subsidiary receives ISCC certification - Enterprise Products announced that its operating subsidiary has received the International Sustainability and Carbon Certification, or ISCC, PLUS certification for facilities within the company's natural gas liquids fractionation and petrochemical complex in Chambers County, Texas. ISCC PLUS is an internationally recognized sustainability certification system providing traceability along the entire supply chain via a mass balance approach for circular, bio, and bio-circular feedstocks. Obtaining the ISCC PLUS certification allows Enterprise to utilize existing assets and systems to expand services for processing, transportation, and distribution of sustainable products across its pipeline network and export facilities.

08:06 EST Pliant Therapeutics receives Orphan Drug Designation from EMA for Bexotegrast - Pliant Therapeutics has received Orphan Drug Designation from the European Medicines Agency, EMA, for the potential treatment of idiopathic pulmonary fibrosis. Bexotegrast is currently being tested in the INTEGRIS-IPF Phase 2a clinical trial in IPF. Pliant presented positive data from the first three dose cohorts of this randomized, double-blind, placebo-controlled trial in July and anticipates topline 12-week data from the 320 mg cohort of patients with IPF, in the first quarter of 2023. "Following the positive interim results from our Phase 2a trial of bexotegrast, we are pleased to receive the EMA's orphan medicinal product designation," said Eric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. "This designation acknowledges the unmet need in IPF, as well as the potential of bexotegrast, and represents an important milestone in the clinical development of this novel drug. We look forward to continuing our work with the EMA and regulators around the globe to advance this therapy for patients in need."

08:06 EST Meta Platforms announces seven new solar projects in Georgia, Tennessee - Meta Platforms announced seven new solar projects in Georgia and Tennessee totaling 720 megawatts, or MWAC, to support its regional operations with 100% renewable energy. Silicon Ranch, one of the nation's largest independent power producers, is partnering with Walton Electric Membership Corporation, or EMC, and the Tennessee Valley Authority, or TVA, to supply the renewable power to serve Meta's data centers in Georgia and the Tennessee Valley, respectively. As part of the agreements, Silicon Ranch will fund, build, own, operate, and maintain the solar facilities over the life of each of the seven projects, bringing significant investment to rural communities throughout the region.

08:05 EST PharmaTher granted orphan drug designation for ketamine - PharmaTher Holdings announced that the U.S. Food and Drug Administration has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation. The Company currently holds four orphan drug designations granted by the FDA for ketamine, which include: Ketamine to prevent ischemia-reperfusion injury from organ transplantation; Ketamine to treat Status Epilepticus, a rare neurological disorder requiring emergency treatment for a seizure; Ketamine to treat Amyotrophic Lateral Sclerosis, a progressive neuromuscular disease with a life expectancy of only two to six years after diagnosis with no known cure; and Ketamine to treat Complex Regional Pain Syndrome, a debilitating condition characterized by severe, continuous, burning or throbbing pain in a limb. Research studies have shown that ketamine lessens the injury from ischemia/reperfusion by inhibiting NF-B thereby suppressing the production of such proinflammatory cytokines as IL-6 and TNF-alpha. Ketamine also shows anti-inflammatory effects by inhibiting the reactivity of leukocytes.

08:02 EST Payoneer Global receives in-principle approval in Singapore - Payoneer has received in-principle approval as a Major Payment Institution License holder from the Monetary Authority of Singapore, or MAS. The license, once received, will allow Payoneer to offer additional payments services such as mass payout and card offerings to companies located in Singapore, effectively empowering businesses of any size with the resources to help them participate and flourish in the new global economy.

07:56 EST Laurentian Bank of Canada increases USD base rate in Canada - Laurentian Bank of Canada increases its USD base rate in Canada by 50 basis points from 7.50% to 8.00%, effective December 15, 2022.

07:53 EST Evaxion Biotech to present readout on two cancer immunotherapies - Evaxion Biotech announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies EVX-01 and EVX-02 in the second quarter of 2023. By mid-2023, Evaxion will present the full clinical readout of EVX-01 in metastatic melanoma and of EVX-02 in patients with resected malignant melanoma. Both compounds are neoantigen-targeting immunotherapies. Evaxion has previously presented interim data for both programs: EVX-01 Phase 1 interim data from 9 patients as previously communicated here: High response rate to the combination treatment, compared to historical data from studies where patients received anti-PD1 treatment alone. The full readout will include results from 13 patients with metastatic melanoma. EVX-02 Phase I/2a interim data from 8 patients as previously communicated here: Robust and long-lasting CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for the DNA-delivery technology. The full readout will include both immune monitoring data and clinical outcome.

07:39 EST Knightscope, ABM announce deployment of three Autonomous Robots - Knightscope (KSCP) and ABM (ABM) announced the deployment of three Autonomous Robots at an international airport parking facility in the U.S.

07:35 EST Trust Stamp engages Marcum as its independent auditor - T Stamp announced the engagement of Marcum, LLP, as the Company's new independent registered public accounting firm. Alex Valdes, Chief Financial Officer, commented, "Marcum is one of the top-ranked accounting firms for rapidly growing small-cap companies, and runs the fifth largest SEC auditing practice in the U.S... With Trust Stamp's offices located in seven countries across North America, Europe, Asia, and Africa, Marcum's international capabilities will be invaluable as we continue to grow our global footprint. Moreover, we believe our selection of Marcum illustrates our commitment to maintaining the highest standards for our financial controls and procedures."

07:35 EST Revive Therapeutics expands private placement to Quebec - REVIVE THERAPEUTICS is expanding its previously announced private placement to investors resident in the Province of Quebec. The Company is arranging a private placement of a minimum of $3 million and a maximum of $5 million of units at a price of $0.15 per Unit. The Offering is being led by EMD Financial. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant of the Company. Each Warrant shall entitle the holder thereof to acquire one additional Common Share at a price of $0.20 for a period of thirty-six months from the closing date of the Offering. As disclosed in the Offering Document, the company intends to use the net proceeds for general working capital purposes and clinical development. In connection with the Offering, the Company will pay finder's fees and issue finder warrants to EMD Financial Inc. as well as any other registrants participating in the Offering consisting of: cash finder's fees of up to 8% of the gross proceeds of the Offering; and finder warrants in an amount equal to up to 8% of the number of Units issued pursuant to the Offering, exercisable at a price of $0.15 per Common Share for a period of thirty-six months following the Closing Date. The Units offered as a part of the Offering shall be offered to purchasers resident in all provinces of Canada, including Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106. The Company may issue up to an aggregate of 33,333,333 Units for maximum aggregate gross proceeds of $5,000,000 under the Listed Issuer Financing Exemption. Units offered under the Listed Issuer Financing Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws. Due to the Offering being expanded to Quebec investors, the Offering is now expected to close in one or more tranches with the first tranche anticipated to close on or before December 30, 2022. Any subsequent tranches may close on or before January 13, 2023, being the end date of the Offering. The closing is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the Canadians Securities Exchange. In addition, the Company expects to submit its Type C meeting request package to the FDA early next week.

07:34 EST Vision Marine receive initial e-motion propulsion system purchase from Beneteau - Vision Marine Technologies has received an initial purchase order from Groupe Beneteau, or Beneteau, of 25 E-Motion 180E outboard and powertrain systems. In addition, at the beginning of each month, Beneteau will provide Vision Marine a quarterly rolling forecast, which shall include additional quantities through a purchase order for the outboard and powertrain systems. Vision Marine and Beneteau will jointly market the groundbreaking Four Winns H2e to Beneteau's dealer network, which includes 72 dealers in the United States, and 400 worldwide, on five continents. The H2e is the first purpose built fully electric runabout available to the market. Four Winns will showcase the H2e and associated technology at the Paris Boat Show, December 3-10, 2022, ahead of the ultimate formal introduction of this innovative new model at the Miami International Boat Show, to be held February 16-20, 2023. "This initial order sets an important commercial milestone and reflects not only the value, but also the trust Beneteau places in our innovative technology, as we expand fully electric propulsion systems globally across Beneteau's formidable portfolio of brands," stated Alex Mongeon, co-founder & CEO of Vision Marine.

07:32 EST Hillenbrand selling Batesville business segment for $761.5M - Hillenbrand has entered into a definitive agreement to sell its Batesville business segment to an affiliate of private equity firm, LongRange Capital, for $761.5M, which includes an $11.5M sub-note. This transaction is expected to close in 1Q23, subject to regulatory approvals and other customary closing conditions. Upon completion of Hillenbrand's divestiture of its Batesville business, Hillenbrand and Batesville will both remain headquartered in Batesville, Indiana. Beginning in its 1Q23, Hillenbrand expects to classify the Batesville business as "held for sale" and anticipates it will report results of the Batesville business as discontinued operations for the current and historical periods in Hillenbrand's consolidated financial statements. Net proceeds from the sale are expected to be used for debt reduction.

07:32 EST Vivos Therapeutics announces new strategic collaboration with Nexus Dental - Vivos Therapeutics announced the creation of a new strategic collaboration with Nexus Dental Systems, which Vivos expects to generate new revenues starting immediately. The agreement between Vivos and Nexus effectively combines Vivos' proprietary out-of-network Billing Intelligence Service with the Nexus' in-network medical billing platform. This collaboration is expected to provide both companies' provider networks with greater access to both in or out-of-network billing with all major medical insurance companies, facilitating case acceptances, insurance billing procedures and reimbursement. "For a long time, medical billing has been a barrier to wide acceptance of dental offices treating breathing and sleep disorders, which is why we have historically offered fee-based out-of-network claims assistance to Vivos providers and their patients," said Kirk Huntsman, Vivos Chairman and CEO. "Our Billing Intelligence Service currently achieves a 98% success rate for reimbursement on out-of-network oral appliance claims, which is extremely high. This new relationship will now give Vivos-trained dentists immediate access to some of the highest in-network reimbursement rates in the industry, allowing higher case acceptance for Vivos-trained providers. We believe this will create immediate additional revenue opportunities, not only for Vivos, but for providers within each network, while patients pay less out of pocket expenses."

07:30 EST Laser Photonics leases additional space in Orlando, Florida - Laser Photonics Corporation announced it leased an additional 7,000 square feet to host its Sales and Marketing Center in Orlando, Florida.

07:27 EST IGEN Networks appoints Juan Ignacio Avila Diaz Rubin as CTO - IGEN Networks announced the appointment of Juan Ignacio Avila Diaz Rubin as Chief Technology Officer. Juan Ignacio Avila Diaz Rubin is the founding partner of Prolog, a global leader and provider of logistics and supply -chain management solutions to over 1200 clients, 80 distribution centers and warehouses with over 250,000 commercial vehicles under management.

07:24 EST RecycLiCo reviews company highlights from 2022 - RecycLiCo Battery Materials reviews the following Company highlights from 2022. Technology Highlights: Commissioned the RecycLiCo Demonstration plant project, achieving successful processing of lithium-ion battery production scrap feedstock; Demonstration plant leach stage exceeded its design capacity, reaching 163% of the planned processing capacity of 500 kg/day of scrap feedstock; Scaled up demonstration plant testing demonstrated impressive leach extraction rates of over 99% for lithium, nickel, cobalt, and manganese; An independent Life Cycle Assessment reported that RecycLiCo's methods have a lower environmental impact compared to other hydrometallurgical recycling and primary mine production; Achieved exceptional lithium recovery rates of over 99% from LFP battery cathode material; Granted patents for lithium-ion battery recycling in Australia, China, and Canada in 2022; Received funding from the National Research Council of Canada Industrial Research Assistance program to support a feasibility study on removal of high concentrations of fluoride from black mass. Business Highlights: The Company received a range of production scrap and black mass feedstock from various sources to test in its hydrometallurgical process; Using this feedstock, the Company was able to produce high-quality battery material samples, such as lithium hydroxide, lithium carbonate, lithium sulfate, and cathode precursor materials for top-tier battery and cathode manufacturers, as well as lithium producers; C4V, an independent battery technology company, successfully used RecycLiCo's NMC811 cathode precursor material to assemble battery cells and validated the performance; Signed multiple Memorandum of Understandings with undisclosed companies, under formal NDAs, to evaluate and develop strategic plans for commercial expansion; Cash on hand of approximately $20M; Changed company name from American Manganese Inc. to RecycLiCo Battery Materials Inc.; Increased business development presence and sponsorship at battery related events and conferences.

07:21 EST Guardian Capital renews normal course issuer bid - Guardian Capital Group announced that it has received approval from the Toronto Stock Exchange for its Normal Course Issuer Bid, pursuant to which it intends to purchase, during the period from December 19, 2022 to December 18, 2023, up to 137,468 or 5% of its outstanding Common Shares, entitled to one vote per share, and up to 1,623,612 or 10% of its public float of Non-Voting Class A Shares as at December 5, 2022. Shares may also be purchased by the trustee for Guardian's employee profit sharing plan, which purchases will count against the maximum numbers of shares which may be purchased by Guardian. In each case, these shares will be purchased at market prices, on the TSX, other designated exchanges and/or alternative Canadian trading systems. All shares purchased by Guardian will be cancelled. Guardian intends to purchase the shares because it believes that, from time to time, the shares may become undervalued at prevailing market prices, based on Guardian's earnings and prospects and accordingly, Guardian is of the opinion that the purchase of shares for cancellation is an appropriate use of corporate funds to increase shareholder value. Pursuant to its most recent Normal Course Issuer Bid, under which Guardian sought and received approval from the TSX to purchase up to 137,469 Common Shares and 1,706,357 Class A Shares for the period from November 23, 2021 to November 22, 2022, Guardian and the Trustee purchased, 0 Common Shares and 872,743 Class A Shares at an average purchase price of $33.68 per Class A Share. These shares were purchased on the TSX and alternative Canadian trading systems. As of December 5, 2022, there were 2,749,379 Common Shares and 23,497,207 Class A Shares issued and outstanding and the public float of the Class A Shares was 16,236,126 shares. The average daily trading volume for Guardian's shares on the TSX during the period from June 1, 2022 to November 30, 2022, excluding purchases made by Guardian under its Normal Course Issuer Bid and by the Trustee during the same period, was as follows: 406 Common Shares; and 5,725 Class A Shares. Except as otherwise permitted by the TSX, daily purchases under the bid will be limited to 1,000 Common Shares and 1,431 Class A Shares, other than block purchase exceptions.

07:18 EST Nasdaq welcomes 156 IPOs, 29 exchange transfers in 2022 - Nasdaq announced that in 2022 it welcomed 156 initial public offerings, raising a total of $14.8 billion. A total of 85 operating companies and 71 SPACs listed on Nasdaq this year, representing an 89%-win rate in the U.S. market, and extending Nasdaq's leadership to 36 consecutive quarters. In addition to IPOs, there were 29 exchange transfers to Nasdaq.

07:16 EST Genprex licenses additional gene technology from University of Pittsburgh - Genprex has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company's existing diabetes technology. The company signed an exclusive license agreement with the University of Pittsburgh in 2020. The gene therapy approach under the original license is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreas. Earlier studies in diabetic mouse models showed that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. It is believed that the duration of restored blood glucose levels in mice could translate to decades in humans. Preliminary data from a more recent study in a non-human primate model of Type 1 diabetes also have been promising. Data from this study are expected to be presented at a scientific meeting during 1Q23.

07:15 EST Marimaca Copper announces results from Marimaca Oxide Deposit - Marimaca Copper announce results from diamond drill hole MAD-22 which intersected high grade primary sulphide mineralization down-dip of oxide mineralization at Marimaca Oxide Deposit. Sergio Rivera, VP Exploration of Marimaca Copper, commented: "The sulphide potential at Marimaca has always presented a compelling exploration opportunity for the Company... While previous drilling into the down-dip geophysical targets identified in 2020 and 2021 intersected additional mixed and secondary sulphides at depth, MAD-22 represents the first significant primary sulphide intersection to date and could represent a primary high grade feeder structure as interpreted in our geological model for the deposit. With the 2022 drill program now completed, results from MAD-22 will be considered in our exploration planning going forward. We look forward to updating the market as our interpretation and plans for additional exploration work are finalized. In parallel and as discussed in previous releases, we will continue with our de-risking strategy at the MOD with the objective of delivering an updated MRE in early 2023, capturing the second half of the 2022 infill program. This will form the basis for the DFS on the Marimaca Oxide Deposit planned for the second half of 2023 or early 2024."

07:14 EST HEXO notes company's 'ability to continue as a going concern' - The company said, "The Company's ability to continue as a going concern is dependent upon its ability in the future to achieve profitable operations and, in the meantime, to obtain the necessary financing to meet its obligations and comply with the related covenants, and to repay its liabilities when they become due. External financing, predominantly by the issuance of equity to the public or debt, will be sought to finance the operations of the Company. On October 31, 2022, the Company had cash and cash equivalents of $78.5 million. Subsequent to Q1'23 on December 5, 2022, the Company's 8% convertible debenture matured and a total of $40.7 million was repaid in respect of the outstanding principal and unpaid interest. Under the terms of the senior secured convertible note, the Company is subject to a minimum liquidity covenant of US$20 million. Thus, there remains a risk that the Company's cost saving initiatives may not yield sufficient operating cash flow to meet its financial covenant requirements, and as such, these circumstances create material uncertainties that lend substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern."

07:12 EST TransAlta sees 2023 adjusted EBITDA $1.20B-$1.32B - TransAlta announced its financial outlook for 2023. Sees 2023 Free Cash Flow of $560M-$660M or FCF per share of $2.07-$2.44, sustaining capital $140M-$170M, expects continued delivery of Clean Electricity Growth Plan by reaching final investment decision on 500 MW of additional clean energy projects across Alberta, the U.S. and Australia to deliver $75M-$100M of incremental adjusted EBITDA. To date, the company has announced 800 MW of projects for a total cost of $1.5B toward its 2 GW Clean Electricity Growth Plan. These projects are expected to deliver $147M of annualized adjusted EBITDA. With the current inflationary environment, expects costs on future projects to be higher based on increases to expected pricing of equipment and construction labor. Sees continuing demand for renewable energy and expects PPA prices to respond to absorb these higher costs across the industry. As a result, forecasts that expected returns on projects will remain intact. Accordingly, resets capital investment target to $3.6B with an increased incremental EBITDA target of $315M.

07:11 EST Domino's Pizza to enter Uruguay and Latvia - Domino's Pizza is continuing to expand its global reach with openings in two new countries, Uruguay and Latvia. The first Domino's store in Latvia recently opened in the city of Riga at Deglava 100 by master franchisee Morgacita Ltd., while the first Domino's store in Uruguay opened in Montevideo at 1163 Luis Alberto de Herrera by master franchisee Alsea.

07:11 EST Hexo CFO says 'substantially lowered' overhead costs - "Over the past six months, we've made favourable amendments to our debt structure and have paid off, in early December, more than $40 million of legacy debt. We've reduced our general and administrative and selling, marketing and promotion expenses by $18 million and have substantially lowered our overhead costs," noted Julius Ivancsits, Chief Financial Officer of HEXO. "We've increased our gross profit before fair value adjustments by approximately $41 million over the previous quarter and have significantly decreased our inventory levels. We've also eliminated unprofitable sales, redeploying those resources into profitable business segments. These actions have paved the way for profitable growth and we're now building positions of strength in those areas where HEXO excels," continued Mr. Bowman. "We've redesigned and upgraded our Masson grow facility, have signed new cultivation agreements, including the partnerships with Entourage and Tilray, and have announced the launch of a top shelf, premium brand, T 2.0, into the Canadian marketplace. Our Redecan brand achieved record sales in the quarter and we've since increased our output of Redees pre-rolls by more than 300% with no capital investment, enabling us to expand our portfolio to meet consumer demand across Canada for these products."

07:10 EST Canadian Solar to start mass production of TOPCon modules in 1Q23 - Canadian Solar announced that its majority-owned subsidiary CSI Solar Co., Ltd. will start mass production of high efficiency N-type TOPCon solar modules in the first quarter of 2023. Canadian Solar's TOPCon modules are best in class and have a power output of up to 690W, and a cell conversion efficiency of around 25.0%, which is 1.5% higher than the average cell efficiency of the mainstream products in the market. Canadian Solar's TOPCon modules will increase energy yield of PV systems and deliver one of the most competitive BOS cost savings and LCOEs for solar power plants, compared to PERC modules. Canadian Solar will provide a diversified portfolio of the TOPCon products to meet the needs for utility-scale, commercial and residential markets. The TOPCon portfolio includes the 182mm cell based bifacial TOPBiHiKu6 (555W-570W) and monofacial TOPHiKu6 (420W-575W) modules, and the 210mm cell based bifacial TOPBiHiKu7 (615W-690W) modules. Canadian Solar will deliver the 182mm cell based TOPCon modules in the first quarter of 2023 and will start mass production of the 210mm cell based TOPCon modules in the second quarter of 2023. TOPCon module shipments are expected to account for around 30% of the company's 2023 total module shipments.

07:09 EST Kimco Realty intends to complete holding company reorganization - Kimco Realty announced that it intends to complete a holding company reorganization, which would restructure the company as an Umbrella Partnership Real Estate Investment Trust, or UPREIT. As part of the reorganization, a new holding company will become the publicly traded parent company by way of an intercompany merger, assuming the existing name of "Kimco Realty Corporation," while the current corporation will convert to a limited liability company called "Kimco Realty OP LLC" controlled by the publicly traded parent company. The reorganization is intended to align the company's corporate structure with other publicly traded U.S. real estate investment trusts and provide a platform for the company to more efficiently acquire properties in a tax-deferred manner. The UPREIT structure will allow owners of appreciated property to contribute such property to an LLC structured as an "operating partnership" in exchange for membership interests therein. Subject to applicable tax requirements, this type of contribution may be done on a tax-deferred basis for the contributors. Following the Conversion, Kimco OP will function as the operating partnership in the UPREIT structure. Membership interests in Kimco OP will generally entitle their holders to receive the same distributions as holders of New Kimco common stock, and the holders of such interests will generally be entitled to exchange the membership interests for cash or common stock, at New Kimco's option. The reorganization is not anticipated to have any material impact on the company's financial position and is not expected to result in any material changes to the Company's combined financial statements, outstanding debt securities, material debt facilities, or business operations. All shares of common and preferred stock of Kimco will automatically be converted into identical shares of the new parent holding company as part of the reorganization, and the reorganization will not impact the payment of the dividends declared by the company's board of directors and payable to stockholders of record in accordance with previously announced dividend payment dates in respect of the company's common shares and the Class L preferred stock and Class M preferred stock. The reorganization does not require shareholder approval under Maryland law and the merger is expected to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code of 1986, as amended, meaning that Kimco's shareholders are not expected to recognize a gain or loss for federal income tax purposes as a result of the merger. The merger is expected to be effective as of January 1, 2023, and the conversion is expected to be effective promptly thereafter. When the reorganization is complete, the holding company will be named "Kimco Realty Corporation," just as Kimco is today, and its shares of common stock, Class L depositary shares and Class M depositary shares are expected to continue to trade on the NYSE under the symbols "KIM," "KIMprL" and "KIMprM", respectively.

07:08 EST Kazia Therapeutics announces pact with QIMR Berghofer Medical Research Institute - Kazia Therapeutics is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centers, to explore novel uses of paxalisib in solid tumours. The research project is led by Professor Sudha Rao, a leading expert in transcriptional biology, particularly as it applies to the function of the immune system in cancer. Professor Rao's laboratory works closely with pharmaceutical companies and with clinicians to explore innovative approaches to cancer treatment. The collaboration is ongoing and will build on initial research that has already led to the filing of a patent, including the use of paxalisib as an immune modulator in the treatment of diseases such as breast cancer. It is anticipated that the results of the research will be published in 1H CY2023, and discussions are ongoing regarding potential translation to clinical trials in CY2023.

07:07 EST Rezolute announces initiation of Phase 2 study of RZ402 - Rezolute announced that the Company has initiated a Phase 2 proof-of-concept study for RZ402, a plasma kallikrein inhibitor, PKI, being developed as an oral therapy for the treatment of Diabetic Macular Edema, DME. "We believe that RZ402 represents the potential for a significant change in the treatment paradigm of DME," said Brian Roberts, M.D., Chief Medical Officer at Rezolute. "By targeting this microvascular diabetes complication with an oral-systemic PKI, analogous to the management of other diabetes complications, RZ402 has the potential to improve overall clinical outcomes by driving earlier treatment intervention and preventing disease progression and vision loss for patients with DME. We look forward to building upon the positive data generated in our Phase 1b trial and remain excited by the broad clinical potential of RZ402 to more effectively treat diseases associated with excessive kallikrein-kinin activity."

07:07 EST Aslan Pharmaceuticals announces first patient screened in study of eblasakimab - ASLAN Pharmaceuticals announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial is expected to enroll 75 patients in North America and will assess the efficacy and safety of eblasakimab in dupilumab experienced patients who have discontinued their treatment for any reason, including inadequate disease control, loss of access to drug or an adverse event. TREK-DX will enable ASLAN to test a once-weekly dosing regimen of 400mg of eblasakimab, which has previously been shown to be safe and well-tolerated in Phase 1 studies that may be the most effective option to address the severity and refractory nature of the disease that these patients experience. TREK-DX will provide support to TREK-AD, a trial that is investigating eblasakimab in biologic naive patients, and could help to strengthen the positioning of eblasakimab as the biologic of first choice for AD treatment. Topline data from TREK-DX is expected in the first quarter of 2024.

07:06 EST Synlogic's SYNB8802 achieves proof of concept in enteric hyperoxaluria - Synlogic announced that SYNB8802 has demonstrated proof of concept through clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery. In the Phase 1b SYNB8802-CP-002 study, SYNB8802 demonstrated a dose-related reduction in urinary oxalate. The -38% urinary oxalate reduction observed at the 3x1011 live cell dose three times a day exceeds the level of urinary oxalate reduction. -20%, that has been associated with reduced risk of kidney stones in analyses based on observational data. SYNB8802 was generally well tolerated. There were no serious adverse events. All GI-related adverse events were mild, and their frequency and severity were similar in the active and placebo group. The primary endpoint was safety and tolerability. Dosing with SYNB8802 was associated with a dose-dependent reduction in urinary oxalate. In addition to the completed SYNB8802-CP-002 study, SYNB8802 is also being evaluated in an ongoing, outpatient study. Full results from both studies will be presented at a future medical meeting.

07:06 EST Paramount Gold Nevada announces results of annual meeting - Paramount Gold Nevada announces the results of the votes from its annual general meeting of the stockholders which was held on December 13, 2022. There were 46,932,378 shares outstanding and entitled to vote at the meeting as of the record date of October 17, 2022, of which, 22,925,414 shares or 48.85 % voted. The stockholders elected the following seven individuals to Paramount's Board of Directors for a one year term expiring at the 2023 Annual General Meeting: Rudi Fronk, Glen Van Treek, Rachel Goldman, Christopher Reynolds, John Carden, Eliseo Gonzalez-Urien, Pierre Pelletier and Samantha Espley. There were 10,630,349 broker non-votes. The stockholders ratified Moss Adams LLP as our independent registered public accountants for the year ended June 30, 2023 with 22,731,882 voting 'for', 35,418 voting 'against' and 158,114 abstaining to vote.

07:04 EST Agora to sell customer engagement cloud business to TI Cloud for $14.6M - Agora announced that it has entered into a definitive agreement to sell the customer engagement cloud business segment of Easemob, which Agora acquired in early 2021, to TI Cloud for approximately $14.6M in an all-cash transaction. "Since our acquisition of Easemob in early 2021, Easemob's chat API business has been integrated with our platform to complement our core product offerings. Earlier this year, we released Agora Chat, which leveraged both Easemob's experience in providing chat APIs and Agora's global infrastructure," said Tony Zhao, Founder, Chairman and CEO of Agora. "As we continue to focus our resources on our core products, the board believes the sale of the other segment of Easemob, namely the customer engagement cloud business, is in the best interest of Agora shareholders as well as employees of that business. TI Cloud is a market leader in customer engagement cloud with a proven record of growth and profitability. We believe this transaction has the potential to create significant product and customer synergies, from which Agora stands to benefit as a shareholder of TI Cloud." The revenues and gross profits attributable to this business segment were approximately $7.2 million and $5.7 million for the year ended December 31, 2020, respectively; and were approximately $8.8 million and $6.3 million for the year ended December 31, 2021, respectively. The transaction is expected to close during the first quarter of 2023, subject to the satisfaction of customary closing conditions.

07:03 EST AbCellera, AbbVie enter strategic collaboration - AbCellera (ABCL) announced that it has entered into a multi-year, multi-target strategic collaboration with AbbVie (ABBV). The partnership will leverage AbCellera's antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications. Under the terms of the agreement, AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

07:03 EST FIS commences comprehensive assessment, adds new Independent Director to Board - FIS' incoming CEO and Board of Directors have initiated a comprehensive assessment of the company's strategy, businesses, operations and structure with the goal of positioning the company to drive stronger results, increase shareholder value and enhance client services. This comprehensive assessment will focus on identifying and optimizing incremental revenue generation, margin improvement and cost reduction opportunities. The review will also evaluate FIS' business structures and portfolio of assets. The company has not set a specific deadline or timetable for its completion. The Board has approved the appointment of a new independent director, Mark Ernst, to the Board. Jeffrey Stiefler and Keith Hughes will be retiring from the Board at the 2023 Annual Meeting. The company is also implementing a new Board leadership structure featuring an Independent Chairman of the Board. The company has entered into a cooperation agreement with the D. E. Shaw group, pursuant to which the D. E. Shaw group has agreed to customary standstill, voting and other provisions. This announcement also reflects discussions with JANA Partners, a shareholder of the company. Mark Ernst currently serves as Managing Partner at Bellevue Capital, a private investment firm, since 2018. From 2011 to 2018, Ernst served as Executive Vice President and Chief Operating Officer of Fiserv.

07:02 EST Hookipa Pharma promotes Schlienger to CMO, appoints Peters to board - HOOKIPA Pharma (HOOK) announced the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer, CMO, and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. Dr. Schlienger has been promoted to Chief Medical Officer. She has served as the Company's Executive Vice President, Clinical Research and Development since July 2022. Dr. Peters serves as Chief Research and Development Officer at MorphoSys (MOR) and will retire from the company at the end of 2022.

06:55 EST Medtronic announces first patient enrolled Expand URO U.S. clinical trial - Medtronic announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo(TM) robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital in Durham, N.C.

06:47 EST Merck, AstraZeneca: FDA to extend PDUFA date for sNDA for LYNPARZA combo - AstraZeneca (AZN) and Merck (MRK) announced that the U.S. FDA has informed AstraZeneca that the agency will extend by three months the Prescription Drug User Fee Act date for the pending supplemental new drug application for LYNPARZA in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. The purpose of the extension is to provide further time for the full review of the submission. The companies will continue to work with the FDA to facilitate the completion of the agency's review. The sNDA for LYNPARZA in combination with abiraterone and prednisone or prednisolone is based on the Phase 3 PROpel trial, results of which were published in NEJM Evidence in June 2022. The application was granted priority review, and AstraZeneca and Merck are committed to working with the FDA to bring this treatment option to patients with mCRPC.

06:05 EST Reviva Pharmaceuticals' brilaroxazine shows positive Phase 3 safety results - Reviva Pharmaceuticals announced positive data from its recently completed clinical drug-drug interaction study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects. The CYP3A4 enzyme plays a pivotal role in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine. DDI evaluation is a critical clinical pharmacology study required by the FDA and other regulatory agencies globally for approving a new drug to market. Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for the treatment of schizophrenia. The company expects to submit these data to the FDA along with the results from pivotal Phase 3 trials as part of its New Drug Application for brilaroxizine in schizophrenia. A strong CYP3A4 inhibitor, itraconazole, slightly increased brilaroxazine Cmax, AUClast and AUCinf by 6, 16 and 13%, respectively, in healthy volunteers. Similarly, a strong CYP3A4 inducer, phenytoin, in healthy volunteers decreased brilaroxazine Cmax, AUClast and AUCinf by 33, 56 and 53%, respectively. Reviva believes that brilaroxazine's clinical safety is further reinforced with the positive results of this DDI study, which found no clinically significant interaction when combined with a CYP3A4 inhibitor. Brilaroxazine is currently being evaluated in a pivotal global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo. Topline data is expected in mid-2023.

06:02 EST BigCommerce announces restructuring plan, to reduce workforce by 13% - BigCommerce Holdings announced its plan to reduce its cost structure and accelerate its path to profitability. The planned restructuring aims to move forward its adjusted EBITDA breakeven timeline from mid to late 2024 to the fourth quarter of 2023. BigCommerce will prioritize its strategic focus, investments and resources to build upon its expanding leadership position in enterprise ecommerce. Already recognized as a leader in composable commerce and omnichannel selling with a full-featured enterprise B2C and B2B offering, BigCommerce will focus its go-to-market efforts on the enterprise business, where it sees the strongest unit economics and the opportunity for long-term, profitable growth. As part of this restructuring plan, BigCommerce will reduce its sales and marketing expenditures in non-enterprise initiatives and its total workforce by approximately 13% across employees and contractors. BigCommerce expects the workforce changes to be largely complete by December 31, 2022. The company estimates the aggregate costs associated with the reduction in force to be approximately $4.2 million to $4.6 million, primarily consisting of severance payments, employee benefits and related costs, and expects to incur these charges in the fourth quarter of 2022. In conjunction with the reduction in force, BigCommerce is also evaluating its facilities footprint and its continued need for existing space for potential impairment of the right-of-use assets associated with its headquarter facilities. The company estimates the aggregate cost of an impairment will range between $2.0 million and $3.2 million. In addition, BigCommerce is reiterating its financial guidance, as outlined in the its third quarter earnings release issued on November 3, 2022, for both the fourth quarter and the full year 2022, for total revenue and non-GAAP operating loss, excluding any estimated impact of costs incurred in connection with the payment of post-employment benefits to impacted employees and other related restructuring costs BigCommerce may recognize in the fourth quarter of 2022. BigCommerce will provide detailed revenue and non-GAAP operating loss guidance on its February 2023 earnings call.

05:38 EST Castellum CEO Rutger Arnhult to leave his position - Rutger Arnhult has informed the board of directors of Castellum that he has decided to leave his position as CEO of the company. The board is now initiating a process to appoint a new CEO. Castellum has in recent years been in a phase of growth where the company, within its financial policy, has made important investments and acquisitions and thereby strengthened its competitiveness in the Nordic commercial property market. This includes the acquisition of Kungsleden as well as the expansion in Finland and Norway through the acquisition of Kielo and the investment in Entra. This has resulted the company's property portfolio growing from SEK 103B in 2020 to SEK 186B at the end of the third quarter of 2022.

05:33 EST Ericsson extends Independent Compliance Monitor with DOJ - Ericsson announced that it has agreed with the U.S. Department of Justice, or DOJ, and Securities and Exchange Commission, or SEC, to extend the term of the company's Independent Compliance Monitor for one year, to June 2024. In 2019 Ericsson entered into a Deferred Prosecution Agreement, or DPA, with the DOJ and a Consent Judgment with the SEC to resolve violations of the FCPA. As part of the resolution, Ericsson agreed to engage an independent compliance monitor for a period of three years while the company strengthened its culture and established a rigorous anti-corruption, compliance and controls program. This extension will allow the company, under the monitorship, to further embed best in class governance, risk management and compliance frameworks across the organization. The company remains committed to cooperating with the DOJ in connection with the resolution of the breach notification.

05:28 EST Pharming announces new evidence from leniolisib study - Pharming announced data, including new evidence, from an interim analysis of its open-label extension study evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta, or PI3Kdelta, inhibitor, to treat adult and adolescent patients with activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare primary immunodeficiency. Principal investigator V. Koneti Rao, a staff physician in the Primary Immune Deficiency Clinic at the National Institutes of Health in Bethesda, Maryland, U.S., shared the positive findings in an oral presentation at the 2022 Annual Meeting of the American Society of Hematology, or ASH. The ongoing extension study includes 37 patients with APDS aged 12 years or older who, at the time of data cutoff for the interim analysis, had received 70 mg of the selective PI3Kd inhibitor leniolisib twice a day for up to six years and three months, with a median duration on study therapy of 102 weeks. The study was primarily designed to assess the safety and tolerability of long-term leniolisib treatment in adolescent and adult patients with APDS who previously participated in a Phase II/III leniolisib study. The extension study's secondary endpoints are intended to evaluate the efficacy and pharmacokinetics of long-term leniolisib treatment in these patients. The interim analysis found that leniolisib was well tolerated to this point in the study. It also indicated the durability of the efficacy results seen in the randomized, controlled trial, which showed significant improvement over placebo in the co-primary endpoints of reduction in lymph node size and increase in naive B cells. The interim results indicate a favorable long-term impact on the immune dysregulation and deficiency often seen in patients with APDS, with clinical manifestations including infections, lymphoproliferation, autoimmunity, enteropathy, bronchiectasis, increased risk of lymphoma, and early mortality. The majority of adverse events, or AEs, reported in the interim analysis were grades 1 and 2, and included upper respiratory tract infection, headache and pyrexia. Grade 1 AEs are the least severe and grade 5 the most severe. Overall, 13.5% of AEs were study drug-related; these affected five patients and included weight gain, arthralgia, hyperglycemia, and decreased neutrophil count. Of all AEs assessed in the analysis, 16.2% were classified as serious, but none of these were identified as related to study treatment. There was one death among study participants which was identified as not related to study treatment. Among study participants, some experienced reductions in APDS disease markers, with levels of response varying between individuals. Responses included: reduced lymphadenopathy, splenomegaly, and IgM levels; improved or resolved anemia, thrombocytopenia, and lymphopenia and resolved neutropenia in all affected patients. Importantly, 37% of participants who were on immunoglobulin replacement therapy, or IRT, were able to reduce their IRT use while taking leniolisib. Six patients became IRT-independent, with four of those patients having been IRT-independent for 1 to 2.5 years at the data cutoff. As of the data cut-off for the interim analysis, among three patients who had a history of lymphoma prior to the trial, none had a recurrence or new lymphoma while participating in the study.

05:20 EST Ferrari subsidiary renews, expands partnership with EssilorLuxottica - Ferrari announced that Ferrari S.p.A., its wholly-owned Italian subsidiary, has renewed and expanded the partnership with EssilorLuxottica that began in 2016. Under the new multi-year agreement, signed by the two companies and effective from January 1, 2023, EssilorLuxottica will continue to design, produce and market eyewear products featuring the Scuderia Ferrari and Ray-Ban brands. The licensing activities also extend to the first collection of monobrand eyewear featuring the Prancing Horse trademark. EssilorLuxottica sponsorship is also expanding under the new agreement: the Ray-Ban logo, in addition to remaining on the Formula 1 single-seaters, will appear for the first time on the cars and apparel of the official drivers in Competizioni GT, competing in the World Endurance Championship with the Le Mans Hypercar and in a Gran Turismo championship with GT3 cars.

05:13 EST Ericsson subsidiary to divest local customer support business in Russia - Ericsson's wholly owned Russian subsidiary has entered into an asset transfer agreement to divest its local customer support business in Russia to a Russian company owned by former operational managers of Ericsson's Russian subsidiary. The transaction includes a transfer of approximately 40 Ericsson employees, and certain assets and contracts related to the business. The customer support business is a local business engagement that does not involve the export of hardware, software, or related services to mobile operators in Russia. Following Russia's invasion in Ukraine, Ericsson announced the suspension of operations and deliveries to customers in Russia and an orderly wind-down in accordance with applicable sanctions. Approximately 400 Ericsson employees in Russia have been notified of layoffs and have been leaving the company as operations have been discontinued. Going into 2023, Ericsson expects to have a small presence in Russia on a local basis. A legal entity owned by Ericsson will continue to be registered to complete the wind-down and to fulfill legal, contractual, and administrative requirements.